主要资产阶段 01
NDA filed / NDA-BLA stage [CO029, CE010, CV017] 尽调报告
Biosplice Therapeutics
曾名 Samumed 的百亿美元级生物技术公司，OA 资产已到 NDA 阶段——战略上可信，但当前估值支撑陈旧且披露不足
Biosplice 是一家历来融资充足、处于 NDA 阶段的生物技术公司，资产可信度真实存在；但估值锚点陈旧、私募经营指标缺失，结论仍只能是继续研究。
封面要素
公司概况
Biosplice Therapeutics 曾名 Samumed，是一家总部位于 San Diego、2008 年成立的私有生物技术公司，开发靶向 可变 RNA 剪接及相关 CLK/DYRK 生物学的小分子疗法。公司价值叙事主要押在 lorecivivint 上：这是一个膝骨关节炎 项目，已在 2026 年 1 月递交 NDA；此前公司还与中国 Haisco、韩国 Samil 达成美国以外授权交易。更宽的平台仍展示 肿瘤和遗留再生项目，但支持近期企业价值的公开证据高度集中在 lorecivivint，以及公司能否把后期临床进展转成获批、 报销和商业化。
- 成立时间
- 2008-01-01
- 创始人
- Osman Kibar, PhD
- 创立地点
- San Diego, California, USA
- 总部
- San Diego, California, USA
- 产品
- 调控可变 RNA 剪接 / CLK-DYRK 生物学的小分子疗法；主导资产 lorecivivint 是 NDA 阶段骨关节炎项目，额外的肿瘤和 遗留再生项目提供置信度较低的可选性。
- 客户
- 先聚焦风湿病学和骨关节炎利益相关方，美国以外商业化伙伴覆盖中国和韩国；肿瘤可选性更偏长期。
- 商业模式
- 依赖获批的生物技术模式：未来美国产品商业化，与美国以外授权、里程碑付款和潜在版税叠加。
- 阶段
- Private late-stage biotech (NDA-stage lead asset)
- 融资情况
- 2018 年曾报道估值 $12B；2021 年披露融资 $120M；当前估值、现金和条款仍由公司私下持有。
执行摘要
主要优势
- Lorecivivint 已在 2026 年 1 月提交 NDA，Biosplice 手里有真实的后期资产，而不是纯临床前平台故事。
- 历史融资能力很强，包括外界广泛报道的 2018 年 $438M 融资，以及披露的 2021 年 $120M 融资。
- Haisco 和 Samil 的区域授权交易，为 lorecivivint 提供了真实的外部付费意愿信号。
- 更大的平台仍保留肿瘤学和历史管线期权；若核心资产降险，期权价值可能显现。
主要风险
- 当前估值支撑陈旧且间接；已审阅的追踪页面无法替代最新定价轮或已签 term sheet。
- 公开来源没有披露当前现金、烧钱速度、现金跑道、优先股堆叠或期权池条款，无法干净承保入场。
- OA 证据混杂，报销路径不确定，上市准备透明度不足；提交 NDA 不等于商业风险已降下来。
- 2026 年面向散户融资的叙事支撑较弱，不应当作资本化兜底。
未决问题
- 当前 post-money 估值、股权结构所有权、清算优先权和董事会权利均未公开。
- 账上现金、烧钱速度、现金跑道和下行融资计划仍未披露。
- Lorecivivint 的定价、报销和市场准入假设仍缺失。
- 已实现的合作伙伴经济性、里程碑回款和商业化准备证据均未公开。
目录
01公司概况
1.1 身份、阶段与战略定位
Biosplice Therapeutics 更应被看作一家私有临床阶段生物技术公司，而不是商业化药企。公开材料始终把公司锚定在 San Diego，围绕 CLK/DYRK 激酶和可变 RNA 剪接的小分子调控展开，并把 lorecivivint 放在当前企业价值叙事中心。 Dealroom 将成立时间列为 2008 年；公司现有材料则强调现在的 Biosplice 品牌，以及开发改变疾病进程疗法的目标， 而不是递增式症状缓解药物。这个定位对尽调很关键：公司今天没有销售已获批药物，经营身份仍靠管线可信度、监管执行和 后续融资，而不是经常性产品收入。公开记录也显示，Biosplice 仍用平台故事解释骨关节炎、肿瘤、神经和其他退行性疾病的 管线宽度，但外部可见证据压倒性集中在膝骨关节炎。后续章节评估 lorecivivint 之外的可选性时，应以这种集中度为前提。[CO001, CO002, CO003, CO004, CO029, CO030]
| 指标 | 数值 / 状态 | 日期 | 置信度 | 缺口 / 备注 |
|---|---|---|---|---|
| 成立 | 2008（第三方跟踪器） | 2026 公开资料 | 中 | 需要章程文件确认原始法律实体沿革 |
| 总部 | San Diego, CA | 2026 | 中 | 公开记录显示一个已披露总部地址 |
| 阶段 | 私营临床阶段生物技术公司 | 2026 | 中 | 未披露已获批产品收入 |
| 主要资产 | lorecivivint NDA 已提交 | 2026-01-06 | 中 | 获批仍待定 |
| 最近披露的股权融资轮 | $120M 股权融资 | 2021-04-15 | 中 | 2021 年后未公开披露新的定价轮 |
| 公开估值锚点 | 旧 $12B 时代峰值叙事 / 已陈旧 | 2018 年参考 | 低 | 未看到新的公开价格发现事件 |
| 收入运行率 | 未公开披露 | 2026 | 低 | 需要经审计财务报表或董事会材料 |
| 客户数 | 未公开披露 / 商业化前 | 2026 | 低 | 已知未来商业化交易对手；产品客户未知 |
| 员工数 | 未公开披露 | 2026 | 低 | 招聘页没有开放职位，但未说明员工规模 |
汇总官方声明和跟踪器；不可得的私有指标明确标为未披露，而非估算。
[CO001, CO002, CO004, CO013, CO027, CO034]公司的身份、资本、临床证据、合作伙伴和监管依赖，全部汇聚到 lorecivivint。
[CO003, CO004, CO013, CO018, CO020, CO027]紧凑的经营指标显示里程碑可见度较强，但当前商业指标披露偏弱。
各项指标混合了官方事实和有区间的数据库背景；缺失的私营公司指标视为未披露，而不是估算值。
[CO001, CO005, CO010, CO013, CO016, CO017]1.2 领导层、创始人影响与治理覆盖
现有管理层和董事会材料显示，Biosplice 的领导班子不大，但功能上齐全。Erich Horsley 是现任 CEO，Osman Kibar 仍任创始人兼执行董事长，Yusuf Yazici 负责医学战略，Phil Wilson 担任 CFO，Scott Bulcao 负责法律。董事会页面还显示 来自投资方的治理覆盖：Vickers Venture Partners 的 Finian Tan、Sands Capital 的 Stephen Zachary，以及 Ahmed Khizer Khan 和 Simon Faure。这个架构让 Biosplice 在战略、医学、财务和法律事务上都有可见覆盖，但公开记录也提示 明显的关键人物依赖。Kibar 仍是公司长期生物学论点绑定的创始人身份，Horsley 反复出现在商业和融资材料中，Yazici 则是 骨关节炎数据发布里最可见的临床发言人。换句话说，公司有治理结构，但公开叙事仍集中在少数具名高管和投资人身上，而不是 宽广披露的运营团队。[CO005, CO006, CO007, CO008, CO009, CO010]
| 人员 | 职务 | 背景 / 公开覆盖 | 创始人-市场匹配度或职能相关性 | 关键人物依赖 |
|---|---|---|---|---|
| Osman Kibar, PhD | 创始人兼执行董事长 | 创始人身份和长期科学叙事 | 把最初的 Samumed/Biosplice 投资逻辑接到当前公司 | 高 |
| Erich Horsley | 首席执行官 | 主导当前公司和商业化叙事 | 是当前运营和融资信息传递的核心 | 高 |
| Yusuf Yazici, MD | 首席医学官 | lorecivivint 对外可见的临床发言人 | 支撑 OA 试验解读和监管框架 | 高 |
| Phil Wilson | 首席财务官 | 财务、融资、投资人沟通 | 关系到私有融资连续性和未来资本规划 | 中 |
| Scott W. Bulcao | 首席法务官 | 法务和交易支持 | 对许可、IP 和尽调执行很重要 | 中 |
表格覆盖公开管理层页面目前列出的高管。
[CO005, CO006, CO007, CO008, CO009]| 利益相关方 | 角色 | 控制权 / 经济重要性 | 尽调要求 |
|---|---|---|---|
| Osman Kibar | 创始人 / 执行董事长 | 科学与治理影响力看起来居于核心 | 核实当前持股、投票权和融资控制条款 |
| Vickers Venture Partners | 董事会关联投资人 | 通过 Finian Tan 拥有可见董事会席位 | 索取逐轮持股和保护性条款 |
| Sands Capital | 董事会关联投资人 | 通过 Stephen Zachary 拥有可见董事会席位 | 索取基金持股和任何信息权 |
| Eventide / aMoon | 2021 年融资新进入者 | 体现专科生物技术投资人支持 | 确认 2021 年之后是否仍然活跃 |
| SymBiosis / Verition / 其他 | 据报道的轮次参与方 | 2021 年扩大了私有投资人基础 | 与股权结构表核对确切持仓 |
| Haisco 和 Samil | 区域商业化合作伙伴 | 潜在的非稀释性验证和商业化杠杆 | 审阅里程碑安排、版税和终止权 |
图谱聚焦已披露投资人和区域合作伙伴；它们对资本可得性或商业化有可见影响。
[CO010, CO011, CO015, CO018, CO019, CO020]从创立到 2026 年 NDA 递交，公开时间线显示商业化路径漫长且并非线性推进。
[CO002, CO013, CO018, CO019, CO020, CO021]1.3 资本历史、投资人和估值模糊性
2021 年更名后，最清楚披露的融资事件是 2021 年 4 月 $120 million 股权融资；公司把这笔钱直接连到 lorecivivint 和 更宽的可变剪接平台议程。2021 年 3 月和 2022 年 8 月的 SEC Form D 文件证实，更名后 Biosplice 仍处在私募融资模式， 但这些公开文件本身不给出新的市场出清估值。估值语境反而来自第三方追踪网站。Dealroom 仍呈现一家 2008 年成立、位于 San Diego、带有旧百亿美元独角兽名声的生物技术公司；Caplight、Seedtable、Tracxn 和私募市场交易页面保留历史融资轮参考， 但没有在公开域浮现干净的 2021 年后重定价事件。投资人因此面对旧估值锚问题：Biosplice 仍带着 2018 年 $12B 时代叙事的 记忆，但公开证据集对融资时间线的支撑远强于对当前公允价值的支撑。据称的 2026 年零售融资若属实，可能显著改变判断； 但在已审阅来源集中，它仍是低置信度，且未获公司官方渠道确认。[CO013, CO014, CO015, CO016, CO017, CO034]
| 事件 / 锚点 | 日期 | 价值 / 状态 | 证据类别 | 含义 |
|---|---|---|---|---|
| 2021 年股权融资 | 2021-04-15 | 已披露 $120M | 官方 + SEC 佐证 | 更名后最具体的新股融资事件 |
| SEC Form D 备案 | 2021-03-03 | 已提交 | 一手监管文件 | 支撑私有融资的连续性 |
| SEC Form D 备案 | 2022-08-24 | 已提交 | 一手监管文件 | 显示后续豁免发行活动 |
| 旧估值叙事 | 2018 年峰值期 | $12B 时代跟踪器锚点 | 第三方跟踪器 | 公开估值已陈旧，近期定价轮未刷新 |
| 2026 年合格投资人股权交易资料 | 2026 | 仅二级市场挂牌 | 第三方市场数据 | 显示市场兴趣，但不是公司认可估值 |
| 2026 零售募资叙事 | 2026 | 未确认 / 相互冲突 | 低置信度新闻 | 投资判断前需要一手文件 |
尽量使用直接披露的资本事件；估值项目若仅由跟踪器或低置信度市场页面支撑，则单独标记。
[CO013, CO016, CO017, CO034, CO035, CO039]1.4 里程碑、区域合作与执行信号
公司的里程碑记录有正有负，并非线性推进。积极一面是，Biosplice 把 lorecivivint 从长期骨关节炎项目推进到 2026 年 1 月 NDA 递交，与中国 Haisco、韩国 Samil 签署区域交易，并借助论文、会议报告和肿瘤试验启动，让更宽管线保持可见。 消极一面是，公开里程碑轨迹也说明，投资人不应把 NDA 视为故事已完全去风险。2022 年，公司承认更早的 3 期试验在全人群中 未达到主要疼痛终点；2024 年 4 月，公司又披露 OA-21 也未达到 12 周主要终点，尽管 OA-07 继续显示更有利的长期结构和 症状轮廓。因此，时间线本身很重要：Biosplice 不是靠连续命中一路走向获批，而是在混合 3 期证据、亚组解读和监管沟通中推进。 2026 年递交因此是重大里程碑，但不足以让人忽略路径依赖和数据解读风险。[CO018, CO019, CO020, CO021, CO022, CO023]
| 日期 | 事件 | 类型 | 金额 / 状态 | 参与方 | 含义 |
|---|---|---|---|---|---|
| 2008 | 公司成立（跟踪器锚点） | 创立 | 2008 年成立 | 旧 Samumed/Biosplice 实体 | 说明公司年龄和漫长研发历程 |
| 2015-09 | OA 2 期研究启动 | 产品 | OA-02 临床项目 | Biosplice 与 ClinicalTrials.gov | 显示临床开发周期很长 |
| 2021-04 | Biosplice 完成股权融资 | 融资 | $120M | Eventide、aMoon、SymBiosis、Sands、Verition 等 | 提供更名后资本支持 |
| 2021-04 | 韩国区域权益授权 | 合作 | 授出商业化权益 | Samil | 增加美国以外商业化路径 |
| 2021-09 | 中国区域权益授权 | 合作 | 总价值 $140M | Haisco | 增加非稀释性合作经济条款 |
| 2022-11 | 披露混合的 3 期数据 | 反向 | OA-10/OA-11 在全人群中未达到主要终点 | Biosplice | 引入解读风险 |
| 2022-11 | 与 FDA 讨论后推进 OA-21 设计 | 监管 | 研究已规划 / 预计入组 | Biosplice + FDA | 显示监管互动活跃 |
| 2023-11 | 展示 OA-07 长期结果 | 产品 | 展示结构和疼痛获益 | Biosplice / ACR | 改善临床叙事 |
| 2024-04 | OA-21 未达到主要终点 | 反向 | 第 12 周疼痛终点未达成 | Biosplice | 获批路径仍有波折 |
| 2026-01-06 | lorecivivint NDA 已提交 | 监管 | NDA 已递交 | Biosplice + FDA | 迄今最大的公开里程碑 |
这是公开可见且与后续章节相关的公司里程碑唯一时间线。
[CO002, CO013, CO018, CO019, CO020, CO021]Biosplice 的公开时间线既有降低风险的里程碑，也有重大执行挫折。
计数仅基于本章审阅的里程碑，属于方向性统计，并非穷尽公司完整历史。
[CO013, CO018, CO020, CO021, CO026, CO027]1.5 概览章节能确定什么，哪些仍未解决
概览章节可以确定公司身份、总部、具名领导层、可见董事会构成、已披露 2021 年融资、区域授权里程碑，以及 2026 年 NDA 递交背后的 事实脉络。它无法确定当前收入、员工数、股权结构表细节、债务敞口，或 2026 年大额零售融资是否真正完成。公开材料也让非 lorecivivint 管线的证据基础弱于公司头部平台叙事所暗示的程度。尽调上，后续章节应把概览作为公司公开身份和时间线的基准事实， 同时继续怀疑没有支撑的规模指标。正确结论不是 Biosplice 没有实质；更准确地说，公开证据最强之处在于 lorecivivint 的监管弧线， 对私有公司的运营指标、当前估值支撑和 2022 年后的资本化则薄得多。这个缺口足够大，任何投资决策都应要求新的第一手材料， 而不是依赖旧独角兽神话或追踪网站外推。[CO029, CO030, CO031, CO032, CO038, CO039]
02市场分析
2.1 市场边界与机会口径
Biosplice 的可触达市场不应被框成全部关节炎支出，甚至也不是全部骨科干预支出。公开证据支持更窄定义：膝骨关节炎患者在长期症状管理路径中 反复切换，且可能接受一种关节腔内注射，目标是同时带来症状缓解和结构性获益。这个口径排除了类风湿关节炎生物制剂、广义慢性疼痛管理支出、 无关肌骨手术和大多数通用骨科植入物。实际临床中，lorecivivint 进入的照护路径已由运动、体重管理、口服或外用止痛治疗、皮质类固醇注射、 透明质酸注射和最终关节置换主导。因此，本章把相关市场定义为膝 OA 治疗路径：临床医生、支付方和患者在这里决定，是否从聚焦症状的照护升级到 一种新的疾病进程调节注射。这个边界在战略上窄于泛 OA 治疗 TAM，但它才是影响采用和估值的口径。[CM001, CM002, CM010, CM011, CM017, CM032]
| 细分 / 类别 | 纳入的支出或活动 | 排除的支出 | 买方 / 支付方 | 相关性 |
|---|---|---|---|---|
| 膝 OA 疾病修饰注射机会 | 专科医生给药的症状性膝 OA 关节腔内治疗 | 所有关节炎类别和无关骨科支出 | 临床医生 + 支付方 | lorecivivint 的核心可触达市场 |
| 现状保守治疗 | 运动、体重管理、口服 / 外用镇痛药、物理治疗 | 不是 Biosplice 的直接变现路径 | 患者 + 支付方 | 判断采用率的基线替代方案 |
| 现有注射疗法 | 皮质类固醇和黏弹补充剂 | 治愈或结构再生主张 | 临床医生 + 支付方 | 近期最相关竞争集合 |
| 晚期手术治疗 | 关节置换和住院手术 | 上游注射市场 | 医疗服务方 + 支付方 | 重要替代方案，但不在 Biosplice 直接产品范围内 |
边界聚焦膝 OA 治疗决策，而不是泛关节炎市场标题。
[CM001, CM002, CM010, CM011, CM032]从疾病负担到获报销使用，每一步都会筛掉表观市场的大部分。
最后一步为零，因为研究日期时 lorecivivint 尚未获批。
[CM003, CM004, CM005, CM013, CM023, CM036]2.2 用患病人数定规模，比宽泛美元 TAM 更站得住
公开证据更适合用人数来衡量骨关节炎问题，而不是用美元。Biosplice 自己的 OA 页面引用美国约 51.9 million 成年人、全球 527.8 million 成年人患有骨关节炎；2026 年 NDA 发布则把这些数字四舍五入为美国约 50 million、全球 500 million 以上。两类来源都把美国膝骨关节炎人数放在 约 25 million 成年人。公司还依据自己的试验解读主张，较早期 KL2 和早期 KL3 患者约占其最关心膝 OA 人群的 70%。这本身并不创造一个已经实现的 商业 SAM，但比把某个分析师美元 TAM 直接塞进估值模型更有证据支撑。本报告最稳妥的做法，是把患病率、亚组适格性和临床工作流适配作为主要镜头， 同时保留基于价格的 SAM 和 SOM 硬缺口。[CM003, CM004, CM005, CM006, CM012, CM013]
| 视角 | 发布方 / 方法 | 地域 | 数值 | 置信度 | 局限 |
|---|---|---|---|---|---|
| 全部 OA 成人 | Biosplice OA 页面 / 负担摘要 | 全球 | 527.8M 成人 | 中 | 公司页面引用疾病负担来源，而非原始数据集 |
| 全部 OA 成人 | Biosplice NDA 新闻稿 / 四舍五入负担摘要 | 美国 + 全球 | 美国 ~50M / 全球 500M+ | 中 | 公司四舍五入表述 |
| 膝 OA 成人 | Biosplice OA 页面和 NDA 新闻稿 | 美国 | 24.7M 至 ~25M 成人 | 中 | 近似公开疾病负担数据 |
| 较早期优选亚组 | Biosplice 对 OA-10/OA-11 的解读 | 美国 | 膝 OA 人群约 ~70% | 中 | 亚组占比来自公司解读，而非流行病学共识 |
| 示意性优选亚组人群 | 报告估算，使用 25M * 70% | 美国 | ~17.5M 成人 | 低 | 患病率视角，不是定价后的 SAM 或可触达 SOM |
使用患病率和亚组视角，而不是缺乏支撑的年度美元 TAM 主张。
[CM003, CM004, CM005, CM006, CM013, CM014]不同公开口径都指向巨大的 OA 疾病负担，但无法共同支撑一个已定价的年度收入市场。
这些计数是患病率口径，不是年度收入估算。
[CM003, CM004, CM005, CM006, CM007, CM013]决策链横跨患者、专科注射医生、支付方和证据守门人。
[CM015, CM016, CM025, CM026, CM031, CM033]2.3 买方、用户与支付方地图
lorecivivint 的经济和临床决策链有多层。患者承受疾病负担，但临床医生才是操作用户：诊断阶段、判断注射是否合适，并完成给药。卫生系统和保险方是 经济守门人，因为指南定位和报销决定一种新型注射疗法会成为标准实践，还是继续受限。这点很重要：Biosplice 推出的不是患者自给的零售药，而是 专科医生交付、带有操作属性的产品，必须嵌入骨科、风湿科和运动医学工作流。商业上最有吸引力的患者，似乎是较早期膝 OA 患者：关节结构仍足以支撑 疾病进程调节论点，也希望推迟手术。但公开来源尚未证明，医生会多快采用一年一次或两次注射，支付方又会如何为这种疗法相对既有症状管理注射支付溢价。[CM015, CM016, CM025, CM026, CM031, CM033]
| 细分 | 买方 | 用户 | 支付方 | 工作流 / 采用触发因素 | 预算所有者 |
|---|---|---|---|---|---|
| 有症状的早期膝 OA 患者 | 医疗系统 / 诊所 | 骨科医生、风湿科医生、运动医学医生 | 商业保险方 / Medicare / 患者共付 | 需要超越单纯缓解症状注射的证据 | 医疗福利项 |
| 中重度慢性膝 OA 患者 | 医疗系统 / 诊所 | 注射专科医生 | 商业保险方 / Medicare | 希望推迟手术或改善功能 | 医疗福利项 |
| 区域商业化合作伙伴 | 合作药企 | 本地商业和医学团队 | 合作伙伴资产负债表 | 美国以外上市权和里程碑经济条款 | 合作伙伴 P&L |
| 指南 / 证据把关方 | 专业学会 / 支付方机构 | 临床和 HTA 评审方 | 支付方或公共体系 | 需要持久疗效和安全性证据包 | 药品目录 / 覆盖委员会 |
新型 OA 注射剂的买方、用户和支付方不是同一个角色。
[CM015, CM016, CM025, CM026, CM031, CM033]Lorecivivint 必须穿过专科医生工作流和支付方审查，而不是走简单零售处方渠道。
[CM010, CM011, CM015, CM016, CM017, CM032]2.4 增长驱动与最关键的采用约束
需求侧驱动很直接：骨关节炎患病率大且仍在上升，疾病造成显著疼痛和功能损失，市场仍缺少已获批的疾病进程调节药物。这些因素为一种不止临时镇痛的疗法 留出了真实战略空间。更难的是把未满足需求转成可报销采用。Biosplice 自己的公开发布说明了原因。公司可以指向 OA-07 的长期结构和症状数据， 但也承认更早 3 期研究未达到主要疼痛终点，OA-21 在 12 周时也再次未达标。这些失手不仅影响监管，也影响商业故事，因为新注射疗法若要替代保守照护和 皮质类固醇或黏弹补充剂等熟悉既有方案，支付方和临床医生需要一套清晰证据包。因此，这个市场有吸引力，但也异常敏感：终点设计、亚组选择、报销证明和标签范围 都会左右采用。[CM007, CM008, CM009, CM018, CM019, CM020]
| 驱动因素 / 约束 | 方向 | 时间 | 影响 | 尽调要求 |
|---|---|---|---|---|
| 骨关节炎患病率高且仍在上升 | 正向 | 长期 | 支撑对更好疗法的长期需求 | 结合管理层模型验证可靶向亚群 |
| 骨关节炎尚无获批 DMOAD | 正向 | 当前 | 若疗效获认可，可打开空白市场 | 测试医生和支付方对新品类的接受度 |
| 镇痛 + 结构改善主张 | 正向 | 取决于上市 | 可能区别于仅缓解症状的注射疗法 | 审查标签预期和 HEOR 材料 |
| OA-21 未达主要终点 | 反向 | 当前 | 抬高审批和采用阻力 | 审查完整试验包和亚组计划 |
| OA-10/OA-11 全人群结果不一 | 反向 | 当前 | 显示结果对终点和安慰剂反应敏感 | 评估亚组逻辑的稳健性 |
| 低成本保守治疗根深蒂固 | 反向 | 当前 | 提高溢价报销难度 | 索取定价和准入策略 |
| 既有注射疗法 | 反向 | 当前 | 设定临床和经济性比较门槛 | 搭建竞品和支付方比较包 |
各行把临床证据直接连到市场扩张或延迟风险。
[CM007, CM008, CM009, CM017, CM018, CM019]2.5 市场章节能、不能从公开证据确定什么
本章可以确定市场边界、患病率数量级、既有照护路径、可能的买方-用户-支付方结构，以及为什么这件事虽然开发周期长但机会仍有吸引力。它无法确定清晰年度美元 SAM、 支付方是否愿意为疾病进程调节型 OA 疗法支付溢价，或获批后的真实医生采用曲线。这些不是小遗漏；它们正是把一个临床上可信的市场转成有价值市场的主要变量。 因此，后续财务和估值章节应沿用患病率驱动的市场逻辑，但避免对近期收入或渗透率给出虚假精确。正确的尽调姿态，是把膝 OA 市场看作庞大、临床痛感强、战略上供给不足， 同时对定价、覆盖、上市顺序和专科采用保留具体追问。[CM023, CM024, CM029, CM037, CM038]
03竞争格局
3.1 竞争格局：现有疗法和替代方案比直接 DMOAD 对手更重要
Biosplice 试图进入的市场，已经用几种不同方式解决膝骨关节炎任务，只是还没有已获批的疾病进程调节产品。因此，相关竞争集合必须宽于生物技术同业本身。 它包括 Zilretta 等皮质类固醇注射、多种透明质酸黏弹补充剂、保守治疗，以及最终通往关节置换的手术路径。这个框架很关键，因为买方不需要又一个实验性平台； 他们需要一个理由，离开熟悉的止痛工具，或在手术前更早使用新疗法。公开证据也表明，直接已获批、可提出 DMOAD 式 OA 疗效主张的同类领域仍很薄， 若获批落地，这会帮助 Biosplice。但在现实中，公司仍会被拿来对照那些临床医生已经会注射、支付方已经会报销的疗法。[CP001, CP002, CP003, CP004, CP005, CP006]
| 竞争对手 / 替代方案 | 类别 | 规模 / 状态 | 目标人群 | 差异化 | 局限 |
|---|---|---|---|---|---|
| Lorecivivint | Biosplice 候选药物 | NDA 已提交，待审批 | 膝骨关节炎，尤其较早期患者 | 病程修饰逻辑，叠加疼痛 / 功能改善叙事 | 尚无获批后的商业验证 |
| Zilretta | 既有皮质类固醇 | 已获批商业产品 | 膝骨关节炎疼痛 | 缓释类固醇镇痛 | 无结构改善声明 |
| Synvisc-One | 既有黏弹补充剂 | 已获批商业产品 | 膝骨关节炎疼痛 | 单针 HA 品牌认知 | 症状缓解定位 |
| Monovisc / Orthovisc | 既有黏弹补充剂 | 已获批商业产品 | 膝骨关节炎疼痛 | 便利性或存量基础认知 | 无疾病修饰逻辑 |
| 全膝关节置换术 | 替代手术 | 根深蒂固的下游术式 | 重度或难治性骨关节炎 | 确定性的机械干预 | 侵入性强，位于路径后段 |
直接获批的 DMOAD 同类很少；现实竞争来自既有症状管理和手术。
[CP001, CP002, CP003, CP005, CP006, CP016]Biosplice 在品类野心上有差异化，但存量方案当前市场准备度更强。
坐标轴是有证据支撑的序数评分，不是实测市场份额。
[CP001, CP002, CP005, CP007, CP010, CP030]3.2 Biosplice 的差异化在品类论点，不在商业护城河
lorecivivint 的市场叙事围绕一个想法：它可能通过影响结构和功能，做到不止临时控痛。这正是投资人和临床医生认为它可能显著不同于既有类固醇和透明质酸产品的核心原因。 问题在于，Biosplice 自己的公开证据基础是混合的。公司可以指向 OA-07 的结构和症状数据，但也披露过 OA-21 主要疼痛终点未达标，以及更早 3 期全人群结果混合。 也就是说，产品可能仍有战略差异化，但尚未商业上占优。与成熟既有疗法相比，Biosplice 缺少已获批标签的熟悉度、办公室常规使用和累积报销先例。因此，竞争故事不是 lorecivivint 已经在每个维度更强；而是如果监管方和支付方接受底层证据包，它可能创造一条新维度。[CP007, CP008, CP009, CP015, CP027, CP031]
| 采购标准 | Lorecivivint | Zilretta | Synvisc-One / HA 组合 | Cingal | 手术 |
|---|---|---|---|---|---|
| 镇痛定位 | 是 | 是 | 是 | 是 | 是 |
| 结构改善逻辑 | 是（公司声称） | 无公开声明 | 无公开声明 | 无公开声明 | 不可比 |
| 当前已获批 | 否 | 是 | 是 | 因市场而异 | 是 |
| 专科诊室流程 | 计划中 | 是 | 是 | 是 | 否，手术场景 |
| 报销熟悉度 | 未知 / 待定 | 较高 | 较高 | Unknown | 高 |
证据不足的单元格只保留方向性或未知；厂商页面不能独立证明优势。
[CP007, CP008, CP010, CP018, CP027, CP029]既有方案今天胜在已获批且贴合工作流；lorecivivint 只在差异化品类逻辑上占优。
[CP007, CP010, CP018, CP027, CP032, CP038]3.3 既有分销、报销熟悉度和工作流适配是真护城河
膝 OA 的商业力量不只来自分子新颖性，也来自一种疗法在日常工作流里的位置。Monovisc、Orthovisc、Synvisc-One、Zilretta 和 Euflexxa 等产品 已经按专科注射办公室来定位，其中一些还具备 Biosplice 尚未拥有的清晰分销或覆盖信号。J&J MedTech 围绕 Monovisc 和 Orthovisc 的分销、 Euflexxa 的 Medicare 覆盖措辞、Orthovisc 的庞大装机基础，都指向既有渠道深度。即使公开净价证据较弱，熟悉度本身也是护城河，因为它降低临床医生和支付方的决策摩擦。 因此，Biosplice 不只要赢下一场正面科学论证，还要赢下准入和习惯改变论证。这会抬高切换成本，也让获批只成为竞争的第一步。[CP010, CP011, CP012, CP013, CP014, CP017]
| 产品 | 剂量 / 包装模式 | 价格可见度 | 报销 / 渠道信号 | 影响 |
|---|---|---|---|---|
| Lorecivivint | 新型注射剂；本次审阅来源未公开最终给药方案 | Unknown | 等待 FDA 和支付方审查 | 商业模式仍属推测 |
| Monovisc | 单次注射 | 公开价格透明度弱 | J&J MedTech 分销信号 | 便利性可帮助采用 |
| Synvisc-One | 单次注射 | 公开价格透明度弱 | HCP 定位稳固 | 诊室流程熟悉 |
| Orthovisc | 每周注射一次，共三或四次 | 公开价格透明度弱 | 存量基础大；美国分销说明指向 J&J 关联 | 就诊负担更高，但熟悉度高 |
| Euflexxa / Hyalgan | 多针 HA 方案 | 公开价格透明度弱 | Euflexxa 突出 Medicare Part B 报销 | 报销熟悉度重要 |
公开竞品页面很少披露可用的净价，因此包装和准入信号分析权重更高。
[CP011, CP012, CP013, CP017, CP018, CP019]竞争耐久性带条件：Biosplice 的逻辑强，但当前准备度弱。
[CP001, CP010, CP023, CP026, CP039]3.4 组合宽度带来可选性，也可能稀释焦点
公司并非纯粹的膝 OA 商业化故事。ClinicalTrials.gov 和 NCI 材料显示，Biosplice 仍在推进 SM04755 和 cirtuvivint 等肿瘤项目。这可以被正面解读为 可变剪接平台不止适用于一个资产；在资本稀缺时，也可以被负面解读，因为管理层注意力和现金可能必须同时支撑多个项目。已终止的 SM08502 联合用药研究提醒人们， 组合决策会因商业原因改变，而不只是科学原因。放在竞争分析里，主要含义是 Biosplice 可能比单资产生物技术公司有更多战略选项，但也面对成熟既有注射品牌没有的内部配置挑战。 这不是直接产品竞争对手，却是一个真实的竞争就绪度变量。[CP022, CP023, CP024, CP025, CP035]
3.5 护城河耐久性取决于标签强度和支付方接受度，不只是新颖性
如果 lorecivivint 上市，它的护城河会来自率先进入一个潜在新疾病进程调节 OA 品类，而不是已经拥有分销。若标签支持“结构 + 症状”的差异化故事，这会很有力量。 若标签狭窄、采用缓慢，或既有厂商用合约和便利性回应，它也可能很快蒸发。公开数据还不能让本章证明强 IP 耐久性、真实医生切换份额或精确价格竞争。正确结论因此是有条件的： Biosplice 可能拥有有意义的论点护城河，但既有厂商眼下在信任、报销熟悉度和商业耐久性上更强。下一步最重要的尽调追问，是完整标签经济性、医生切换意愿，以及准入策略如何抵消 根深蒂固的工作流习惯。[CP026, CP028, CP029, CP036, CP037, CP039]
04财务情况
4.1 收入模式仍以未来为主
公开证据没有显示 Biosplice 今天拥有确认产品收入的运营业务。研究日时，lorecivivint 仍未获批，因此最站得住的财务框架仍是未来性，而不是已实现。可见变现路径包括： 若获批落地，未来美国产品销售；与 Haisco、Samil 等伙伴的美国以外授权经济性；以及只有在合作推进后才可能出现的后续里程碑或版税流。这与一家拥有当前经常性收入或已披露商业销量的公司 完全不同。因此，本章把 Biosplice 视为一家经济模型依赖获批的后期生物技术公司。若有财务强度，它来自交易可选性和投资人继续资助开发的意愿，而不是已经证明的商业现金生成。[CI001, CI002, CI003, CI004, CI005, CI009]
| 来源 | 机制 | 计量单位 | 当前状态 | 质量 | 尽调要求 |
|---|---|---|---|---|---|
| 美国产品销售 | 获批后直接商业化 | 按治疗患者 / 注射计 | 尚未启动 | 当前可见度低 | 索取上市模型和定价假设 |
| 中国授权 | 首付款 + 里程碑款 + 可能的特许权使用费 | 已签约伙伴经济条款 | 已公开宣布 | 名义价值中等，会计可见度低 | 索取收款计划和特许权使用费条款 |
| 韩国授权 | 首付款 + 里程碑款 + 可能的特许权使用费 | 已签约伙伴经济条款 | 已公开宣布 | 名义价值中等，会计可见度低 | 索取收款计划和特许权使用费条款 |
| 其他管线合作 | 未来选择权 | Unknown | 未公开量化 | 低 | 索取 BD 管线和条款清单状态 |
公开收入证据主要是或有授权经济条款，而非已确认销售。
[CI001, CI002, CI003, CI004, CI005, CI025]公开经济收益从审批获批流向合作伙伴里程碑和最终产品销售，而不是当前经营收入。
[CI001, CI002, CI003, CI004, CI009, CI025]4.2 授权经济性可见，商业化路径效率不可见
Haisco 和 Samil 公告是最清楚的公开变现证据，因为它们为区域权益给出了明确合计价值。Haisco 交易被描述为最高 $140 million，包括 $20 million 首付款和早期开发里程碑； Samil 交易被描述为合计价值最高 $70 million。这些数字有助于判断外部伙伴如何给资产定价。它们不等同于已确认收入、账上现金或可重复商业效率。公司阶段仍太早，公开获客成本（CAC）、回本周期或销售周期披露还没有实际意义。 因此，本章的商业化路径分析聚焦地域、合作伙伴结构和或有经济性，而不是类似软件公司的效率指标。对于一家 NDA 阶段、公开商业化细节有限的生物技术公司，这是合适的精度。[CI003, CI004, CI005, CI011, CI012, CI013]
| 价格 / 合同模式 | 标价与实际成交价 | 折扣 / 未知项 | 来源 |
|---|---|---|---|
| Lorecivivint 美国上市价格 | Unknown | 所有实际经济条款均未知 | NDA 新闻稿 / 骨关节炎页面 |
| Haisco 交易 | 总额最高 $140M，含 $20M 首付款 + 早期开发里程碑款 | 特许权使用费和里程碑款瀑布未披露 | 公司 + Fierce + MarketScreener |
| Samil 交易 | 总价值最高 $70M | 收款时点和会计处理未披露 | 公司 + BioSpace + KoreaBioMed |
| 二级市场股价代理 | 仅通知价格 | 非经营性变现；也非经审计估值 | 通知 |
合同名义金额不应误认为已确认收入。
[CI003, CI004, CI005, CI018, CI021, CI023]公开记录披露了合作伙伴交易金额，但大多数直接单位经济输入仍不可得。
[CI010, CI012, CI014, CI015, CI023, CI028]4.3 成本结构轮廓清楚，金额不透明
即便没有经审计报表，大致成本结构也容易推断。Biosplice 为长期临床项目、多轮盲法多中心研究、监管递交工作，以及 NDA 阶段资产所需的上市前生产和医学运营搭建提供过资金。 这些活动都很贵。公开来源几乎没有披露真正建模所需的信息：毛利率路径、货品成本、库存搭建、上市营运资本、月度烧钱速度，或里程碑收款时点。这个区别很重要。本章可以负责任地说 Biosplice 资本密集，但不能负责任地赋予精确利润率轮廓或现金跑道。即使更宽的产品战略案例仍有吸引力，缺少颗粒度也应降低任何近期财务情景的置信度。[CI014, CI015, CI016, CI022, CI023, CI028]
| 指标 | 数值 / null | 置信度 | 重要性 | 尽调要求 |
|---|---|---|---|---|
| 毛利率 | null | 低 | 判断生物技术产品上市经济性所需 | 索取 COGS 和生产假设 |
| 单针生产成本 | null | 低 | 决定获批后的盈利能力 | 索取配方和灌装完成成本估算 |
| 营运资本需求 | null | 低 | 上市库存会吃掉现金 | 索取库存建设和付款条件 |
| 获客成本（CAC） | null | 低 | 商业销售团队模式未知 | 索取上市人员配置和渠道计划 |
| 销售周期 / 报销周期 | null | 低 | 决定爬坡速度 | 索取支付方准入和客户排序计划 |
空值是刻意保留的，因为公开记录不足以支撑伪精确。
[CI010, CI011, CI014, CI015, CI023, CI028]即便实际现金流数字不可见，资本强度仍看得见。
[CI014, CI016, CI018, CI019, CI032, CI034]4.4 资本充足性仍是最大财务未知数
公开记录清楚显示，Biosplice 多次募集私募资本，包括 2021 年股权融资和多份 Form D 文件。记录也显示，公司用区域授权补充围绕 lorecivivint 的融资故事。 没有显示的是当前流动性。Form D 文件和新闻稿都没有给出经审计账上现金、月度烧钱速度、现金跑道月数，或实时优先股堆叠。NDA 递交可能提升融资杠杆，因为监管审评会压缩外界感知的开发风险， 但它不能证明公司资金足以支撑上市。未经验证的 2026 年零售融资说法让图景更复杂：若属实，影响重大；但在保留来源集中，支撑较弱。正确的公开数据立场是： Biosplice 依赖融资，NDA 后位置可能更好，但并未可证明地资本充足。[CI006, CI007, CI008, CI016, CI017, CI020]
| 项目 | 公开信号 | 置信度 | 影响 | 尽调要求 |
|---|---|---|---|---|
| 2021 年股权融资 | 公司宣布 $120M 股权融资 | 中 | 显示其具备外部融资能力 | 索取投后股权结构表和资金用途桥表 |
| 2021/2022 年 Form D 活动 | 私募发行得到佐证 | 高 | 更名后融资活动仍在继续 | 索取已完成的确切金额和剩余承诺 |
| 当前账面现金 | null | 低 | 主要未解投资判断变量 | 索取最新资产负债表 |
| 月度烧钱速度 | null | 低 | 测算现金跑道月数所需 | 索取过去 12 个月现金流量表 |
| 现金跑道月数 | null | 低 | 判断上市依赖度所需 | 索取董事会批准的现金跑道计划 |
| 2026 年散户融资 | 叙事支撑较弱 | 低 | 若经验证，可能实质改变现金跑道 | 索取认购文件和结算证据 |
历史融资事实不能替代当前流动性披露。
[CI006, CI007, CI008, CI016, CI017, CI020]| 缺失的私有指标 | 影响 | 精确尽调路径 |
|---|---|---|
| 账面现金和非受限流动性 | 无法判断现金跑道 | 索取最新经审计资产负债表和资金明细表 |
| 月度烧钱速度和经营现金流 | 无法判断融资依赖度 | 索取过去 12 个月逐月现金流 |
| 优先股堆叠和稀释压力 | 无法判断增量融资质量 | 索取完全摊薄股权结构表和条款摘要 |
| 来自伙伴的已确认收入 | 无法区分入账收入和或有价值 | 索取收入确认备忘录和合同附表 |
| 上市定价 / 支付方假设 | 无法搭建收入模型 | 索取定价架构和市场准入计划 |
这些缺口是精准测算的主要障碍。
[CI022, CI023, CI024, CI029, CI031, CI035]对融资事实，只能支撑粗略公开区间；现金跑道仍不可得。
此处现金跑道为零，仅是已验证公开数据不可得的占位符，并不表示公司没有现金。
[CI003, CI004, CI006, CI016, CI022]4.5 财务结论：战略价值存在，运营披露不足
从财务尽调角度看，Biosplice 的价值仍由按概率加权的未来经济性驱动，而不是当前运营质量。正面论点很清楚：多年临床投入、真实的美国以外伙伴经济性，以及至少已经进入 NDA 审评的产品。 限制因素同样清楚：公开来源没有披露当前现金、烧钱速度、已实现伙伴收款、上市定价，或资本结构机制。这意味着正确财务结论不是看空其野心，而是对可承销性保持谨慎。若获批、定价和上市执行同时对齐， 公司可能很值钱；公开记录只是无法让投资人精确证明这个案例。后续估值工作因此应保持情景化，并强烈依赖缺失的私有财务披露。[CI018, CI019, CI024, CI025, CI026, CI031]
05产品与技术
5.1 从工作流看，产品是什么
Biosplice 不是在向终端用户销售工具包或平台订阅。其公开主导产品是 lorecivivint，一种由临床医生给药、用于膝骨关节炎的关节腔内注射。从工作流看， 这意味着疗法位于骨科或风湿科专科照护中，评估标准是疼痛、功能和结构结果，而不是消费者激活指标。使用点上的产品架构相对简单：识别合适患者，完成单次注射， 并随时间追踪临床结果。复杂性在上游：分子设计、试验执行、监管审评和上市准备。这个区别很重要，因为它改变了“成熟”的含义。生物技术产品可以在科学上高度成熟， 但在生产、质量或支持运营上仍商业不透明。公开来源让本章可以有把握地描述药物、给药模式和关键证据闭环。[CE001, CE002, CE005, CE025, CE029]
| 用户任务 | 当前工作流 | Biosplice 方案 | 可衡量收益 | 限制 |
|---|---|---|---|---|
| 治疗有症状膝 OA | 门诊就诊并决定是否注射 | 单次关节腔内注射 lorecivivint | 疼痛 / 功能改善，外加可能的结构信号 | 尚待获批 |
| 识别剂量和响应人群 | 临床试验给药与评估 | 早期研究选定 0.07 mg | 后期项目聚焦该剂量 | 仍存在亚组敏感性 |
| 记录疾病活动度 | 疼痛 NRS、WOMAC、患者总体评估 | 核心终点在多项研究中复用 | 可比证据包 | 终点在后期研究中仍然喜忧参半 |
| 评估结构变化 | 放射影像 mJSW / X-ray | 项目设计纳入结构指标 | 超越镇痛的差异化 | 结构改善主张能否被商业接受尚未定论 |
产品工作流以临床和证据为重，而不是靠数字化工具驱动。
[CE001, CE002, CE005, CE006, CE007, CE008]OA 产品从患者筛选走向专科注射，再进入长期结局随访。
[CE001, CE005, CE014, CE029]5.2 资产地图与平台宽度
公司的公开产品集合宽于单一骨关节炎资产。lorecivivint 是主导资产，也是已审阅来源集中唯一递交 NDA 的资产，但论文和试验记录还显示 SM04755、SM08502 和 cirtuvivint 等肿瘤项目。这点重要，因为底层平台故事是跨多个疾病领域控制可变剪接，而不是一次性 OA 化学。它也重要，因为平台宽度会改变投资人对技术可选性和管理层焦点的判断。 若学习能跨项目迁移，更宽资产地图会增加价值；它也可能带来资本配置和执行取舍。从产品与技术角度看，正确结论是 Biosplice 已展示足够公开宽度，可以被视为平台公司； 但公开运营细节不足，无法判断平台在项目之间扩展得多高效。[CE011, CE012, CE013, CE026, CE030, CE035]
| 资产 / 模块 | 主要用户 | 状态 / 成熟度 | 差异化 | 尽调缺口 |
|---|---|---|---|---|
| Lorecivivint（OA） | 注射专科医生 | NDA 已提交 / 审评阶段 | 潜在改变 OA 病程的逻辑 | 上市运营未公开 |
| SM04690 2 期证据基础 | 临床开发团队 | 已完成 | 剂量探索和终点设计 | 商业转化不清晰 |
| SM04755 肿瘤项目 | 肿瘤研究者 | 1 期已完成 | 体现更宽的剪接平台 | 公开材料里看不到清晰商业路径 |
| SM08502 肿瘤项目 | 肿瘤研究者 | 研究已终止 | 平台覆盖更宽 | 业务终止理由披露有限 |
| Cirtuvivint 肿瘤项目 | 肿瘤研究者 / NCI 研究站点 | 研究仍在推进 | OA 之外的平台选择权 | 相比 OA 的经济优先级不清晰 |
公开资产图谱能证明平台广度，但各项目成熟度并不相同。
[CE001, CE011, CE012, CE013, CE030, CE035]OA 临床成熟度高，但商业化运营的公开可见度低。
[CE011, CE020, CE022, CE032, CE033, CE037]5.3 机制、证据设计，以及临床栈实际做了什么
lorecivivint 的公开机制叙事从 Wnt 通路调节开始，并把这种生物学与 CLK2/DYRK1A 抑制和可变前体 mRNA 剪接连接起来。这是公司差异化主张的技术核心。 围绕它搭建的证据栈同样重要：多轮随机盲法试验、剂量探索工作，以及把患者报告疼痛 / 功能与内侧关节间隙宽度等结构影像概念结合的结局框架。公开材料说明了这个项目为何长期保持吸引力。 当结构和症状方向一致时，产品显得最强；当全人群疼痛终点落空、即便其他活性信号存在时，产品显得最弱。这不只是临床细节，而是产品设计问题的一部分，因为疗法的真实世界价值主张取决于 监管方和支付方如何解读这些终点。从这个意义上，证据包就是产品架构的一部分。[CE003, CE004, CE006, CE007, CE008, CE027]
| 层级 / 流程 | 作用 | 依赖 | 风险 |
|---|---|---|---|
| Wnt / CLK2-DYRK1A 生物学 | 机制基础 | 转化有效性 | 机制未必能完整写进获批标签 |
| 单次注射制剂 | 给药方式 | 临床医生给药 | 工作流采纳取决于专科医生 |
| 随机盲法试验体系 | 证据生成 | 多中心临床站点网络 | 执行和终点风险 |
| 放射影像 + PRO 终点组合 | 差异化证明 | 监管解读 | 结果喜忧参半会模糊产品叙事 |
| 监管申报包 | 商业化路径 | FDA 审评 | NDA 结果未知 |
生物技术资产的产品架构里，证据包本身就是一环。
[CE004, CE007, CE008, CE014, CE015, CE025]Biosplice 的 OA 产品栈把作用机制、注射给药、证据生成和监管审评串在一起。
[CE001, CE004, CE007, CE010, CE025]产品依赖生物学、多中心试验、监管方和获批后运营系统，而这些公开可见度都不完整。
[CE004, CE014, CE017, CE018, CE024, CE036]5.4 临床开发成熟度高，商业运营可见度低
按生物技术标准，OA 资产已经成熟。公开记录包括 2 期、3 期和现在 NDA 阶段证据。多项试验记录、论文和公司发布提供了清晰里程碑路径：从剂量探索到关键设计，再到监管递交。 这比许多风险投资阶段生物技术资产能展示的成熟度信号强得多。但成熟度并不均衡。来源集大量披露临床设计，却很少披露生产、放行检测、商业药物警戒运营或规模化上市支持。 因此，报告可以把临床开发机器评分为先进，同时仍把运营和质量就绪度视为披露不足。这个缺口不致命，但很重要，因为项目一旦从试验执行转向商业化，缺失细节就会变成最重要的一批产品风险。[CE009, CE010, CE014, CE015, CE023, CE032]
| 日期 / 阶段 | 里程碑 | 状态 | 含义 | 来源 |
|---|---|---|---|---|
| 2015 | ACR 机制报告 | 已完成 | 公开早期机制逻辑已经成形 | ACR 2015 壁报 |
| 2020 | 2a 期论文发表 | 已完成 | 结构 + 症状信号有公开记录 | Samumed 新闻稿 / Arthritis & Rheumatology |
| 2021 | 2b 期论文和事后分析 | 已完成 | 剂量和反应论据增强 | Biosplice 论文 / OARSI 文章 |
| 2022-2024 | 3 期披露喜忧参半；OA-07 结构更新 | 已完成 / 喜忧参半 | 后期证明包仍然复杂 | GlobeNewswire 新闻稿 |
| 2026 | lorecivivint NDA 提交 | 里程碑已完成 | 项目进入监管审评 | NDA 新闻稿 |
路线图在临床里程碑上最清晰，在上市准备细节上最弱。
[CE006, CE009, CE010, CE022, CE032, CE033]5.5 信任与质量主要由研究设计支撑，而非可见运营控制
最强的公开信任信号来自科学和监管，而不是运营。随机、盲法、安慰剂对照研究、同行评议文章，以及稳定的会议海报节奏，都支持一个判断：Biosplice 围绕 lorecivivint 搭建了严肃的证据引擎。安全性和耐受性措辞也在保留来源中反复出现。缺失部分同样重要。已审阅公开材料没有披露商业规模生产伙伴、详细 CMC 控制、放行指标、公开质量体系认证或商业支持基础设施。 这并不意味着控制不存在；它意味着外部投资人无法从公开来源验证。对于一家 NDA 阶段生物技术公司，这是核心未解产品技术问题。因此，本章把研究严谨性和科学参与视为已验证强项， 同时把商业化质量系统和支持就绪度作为明确尽调缺口，而不是推断出的强项。[CE016, CE017, CE018, CE019, CE020, CE021]
06客户情况
6.1 当前实际客户是合作伙伴和临床利益相关方，不是商业用户
本章最大的挑战是定义。Biosplice 还没有软件或医疗器械公司可能展示的那类公开商业客户基础。研究日时，lorecivivint 仍未获批，因此没有经过验证的公开证据显示生产收入账户、 活跃商业治疗患者数或支付方合同。当前最好的客户代理，是更宽的利益相关方集合：Haisco、Samil 等区域商业化伙伴，负责把研究落地的临床研究者和中心，以及用结局构成证据包的患者。 这意味着客户章节讨论的不是已安装收入账户，而是谁已经愿意向项目投入资源、权益和运营时间。这个区别很关键，因为它让分析保持诚实：Biosplice 有真实的外部交易对手和用户参与， 但还没有广泛、可衡量的上市客户基础。[CU001, CU002, CU003, CU014, CU017, CU030]
| 细分 | 买方 / 用户 / 支付方 | 用例 | 规模 / 战略价值 | 缺口 |
|---|---|---|---|---|
| Haisco | 被许可方 / 本地商业运营方 / 区域支付方对接 | 中国开发和商业化权利 | 战略价值高，仅一个具名合作方 | 未公开收入确认细节 |
| Samil | 被许可方 / 本地商业运营方 / 区域支付方对接 | 韩国开发和商业化权利 | 战略价值高，仅一个具名合作方 | 未公开续约或收款细节 |
| 临床研究者和站点 | 研究执行方 / 用户 / 无支付方角色 | 试验执行和证据生成 | 运营覆盖面大 | 不是收入客户 |
| 试验参与者 / 患者 | 试验方案下终端用户 / 无买方角色 / 无支付方角色 | 临床反应生成 | 多项研究入组数百人 | 不是商业化治疗患者基数 |
| 未来支付方 | 潜在买方守门人 | 获批后的报销覆盖和准入 | 可能很关键 | 未公开已签合同 |
实际客户图谱涉及多方，且大多仍处于商业化前。
[CU001, CU006, CU007, CU008, CU017, CU030]当前旅程仍处在商业化前：合作伙伴与试验相关方搭起从证据到未来患者的桥。
[CU001, CU002, CU003, CU006, CU025, CU030]公开证据先指向宽阔疾病机会，最后只落到少数具名商业对手方。
最后一步反映公开商业患者数量不可得，并不是声称不存在未披露患者。
[CU001, CU002, CU003, CU017, CU025, CU034]6.2 具名合作伙伴是最强商业化证据
在保留来源集中，Haisco 和 Samil 是最清楚的具名交易对手。它们的协议很重要，因为协议把 lorecivivint 连到具体地域，也让外部读者看到比标志墙或泛泛商务拓展主张更具体的东西。 Haisco 覆盖中国，Samil 覆盖韩国；多项保留来源相互印证这些关系。这是有意义的证据，说明第三方愿意押注该资产。同时，这些交易仍不等同于成熟客户基础。它们不能证明经常性收入、 续约率或扩张动态，并且把可见合作伙伴故事集中在少数交易对手身上。财务条款是头部价值，不是已实现收款证明。因此，客户结论应保持平衡：这些关系显示真实商业兴趣和外部验证， 但由此形成的客户基础狭窄，且仍高度或有。[CU002, CU003, CU004, CU005, CU020, CU023]
6.3 患者和中心证据真实，但仍属临床证据而非商业证据
最强的终端用户证据来自注册试验和已发表事后分析。大型多中心 OA 研究、数百名入组参与者和具名研究者都显示，Biosplice 能以有意义的规模招募、运行和分析项目。 PMC 事后分析提供了保留集中最干净的患者层面证据，显示主动治疗组更可能出现临床上有意义的疼痛和功能响应。但客户章节也必须保留反向一面。安慰剂与假操作分析提醒读者， 关节腔内 OA 试验可能出现很大的对照组响应效应；2026 年荟萃分析也比纯公司撰写材料更谨慎。这些正是把临床热情转译为未来客户行为时必须重视的细节。 简言之，证据支持利益相关方参与和用户兴趣，但还不能证明商业采用质量。[CU006, CU007, CU008, CU010, CU011, CU012]
| 指标 | 数值 | 日期 | 来源 | 置信度 | 含义 | 缺失分母 |
|---|---|---|---|---|---|---|
| OA-02 入组 | 455 名参与者 | 2021 年更新 | ClinicalTrials.gov API + 研究页面 | 高 | 早期患者参与度强 | 商业转化 |
| STRIDES-1 入组 | 496 名参与者 | 2026 年发布记录 | ClinicalTrials.gov API + 研究页面 | 高 | 后期研究者和患者参与度 | 商业转化 |
| 美国以外具名合作方 | 2 个地区（中国、韩国） | 2021 年交易 | 公司披露 + 独立报道 | 高 | 已有合作方牵引力 | 每段合作关系的经济质量 |
| NCI 赞助研究首例患者给药 | 1 个公开启动里程碑 | 2025 | BioSpace + NCI | 中 | OA 之外的机构利益相关方证明 | 收入相关性 |
轨迹按里程碑展开，不是按账户展开。
[CU002, CU003, CU006, CU007, CU008, CU015]| 客户 / 利益相关方 | 细分 | 部署 / 用例 | 正式使用 / 试点 | 结果 | 限制 |
|---|---|---|---|---|---|
| Haisco | 商业化合作方 | lorecivivint 中国权利 | 准商业化合作合同 | 披露具名地区和经济条款 | 未公开收入实现或上市证明 |
| Samil | 商业化合作方 | lorecivivint 韩国权利 | 准商业化合作合同 | 披露具名地区和经济条款 | 未公开收入实现或上市证明 |
| OA 试验参与者和研究者 | 临床终端用户 / 执行方 | 已注册 OA 研究 | 试点 / 临床证明，不是商业化证明 | 入组数百人，且有已发表结果分析 | 不是付费客户 |
| NCI 赞助 AML/MDS 试验网络 | 机构利益相关方 | 研究运营启动 | 试点 / 临床证明，不是商业化证明 | 首例患者已给药，研究仍在进行 | 不是产品收入 |
具名证明最强的场景，是合作方或机构绑定具体权利或研究，并得到多个维度交叉印证。
[CU002, CU003, CU006, CU007, CU008, CU010]合作伙伴证据更能证明商业化意图；临床证据更能证明用户参与，而不是收入质量。
[CU002, CU003, CU006, CU010, CU015, CU020]公开可见的只有试验随访式耐久性；商业留存仍未知。
取值为 1 表示存在耐久性代理指标证据，不代表留存百分比。
[CU018, CU019, CU026, CU027]6.4 留存基本是空白；集中度显然很高
公开留存证据很弱。公司没有披露 NRR、GRR、流失、合同续约或复购指标。试验随访和重复给药设计只能作为间接代理，因为它们捕捉的是方案化参与，而不是真实客户复购意愿。 相比之下，集中风险很容易看见。可见的美国以外合作伙伴故事集中在少数具名交易对手身上，整体客户叙事也围绕一个主导 OA 资产集中。这不让公司失去吸引力， 但从尽调角度看，客户基础多元化不足。若获批落地，少数合作伙伴和支付方决策可能产生不成比例的影响。在此之前，正确分析动作是让大多数留存字段保持空值， 并强调集中度、利益相关方类型和下一批证明里程碑。[CU018, CU019, CU023, CU024, CU026, CU027]
6.5 客户结论：真实的利益相关方拉力，有限的商业可见度
Biosplice 的客户式证据强于原始临床前故事，但弱于已上市商业公司。合作伙伴一侧真实且具名；患者和研究者一侧真实，并绑定注册研究和论文；机构证明甚至延伸到 NCI 赞助的肿瘤工作。 缺失的是完整商业层：已执行的支付方覆盖、活跃商业治疗患者、重复购买、试验外满意度和扩张动态。结果是一个有层次但一致的结论。Biosplice 看起来能够围绕主导项目吸引严肃利益相关方， 这很有价值。但公开证明还不足以声称它拥有多元、耐久、可衡量的客户基础。与合作伙伴 logo 本身相比，这个缺口更应影响后续风险和估值判断。[CU015, CU016, CU017, CU030, CU032, CU036]
07风险
7.1 监管和法律风险主导当前风险栈
Biosplice 周围的主导风险仍是监管和证据。lorecivivint 已进入 NDA 审评，这是重大成就；但这个阶段也会把注意力集中到临床包里所有剩余弱点上。混合的 3 期结果、 有记录的 OA-21 主要终点失手，以及比公司自写信息更谨慎的外部荟萃分析，都强化了一个事实：获批不是走过场。法律一侧，公开专利转让记录显示 Biosplice 拥有有意义的 IP 资产， 但它们没有回答可执行性、到期时间或自由实施问题。更少见的是，公开条款和隐私页面似乎缺失，形成一个较小但值得注意的治理缺口。这些法律事项都不比获批问题更重要， 但它们属于尽调风险栈，因为它们关乎公司对投资人和交易对手的准备度与外部透明度。它们也帮助界定法律尽调何时应停止依赖表层网页证据，转入法律顾问主导的文件审查。[CR001, CR002, CR003, CR004, CR008, CR009]
| 风险 | 司法辖区 / 背景 | 状态 | 可能性 | 严重性 | 缓释措施 | 剩余敞口 | 尽调路径 |
|---|---|---|---|---|---|---|---|
| 获批或药品标签风险 | FDA / 美国 OA 项目 | 未关闭 | 中 | 高 | 已提交 NDA，包含多项研究资料 | 高 | 审阅完整 NDA 和可能的标签情景 |
| 后期疗效信号不一致 | 临床证据包 | 存在 | 高 | 高 | 亚组与结构论证 | 高 | 检查完整试验报告和敏感性分析 |
| 专利范围 / 可执行性不确定 | IP / 法务 | 未关闭 | 中 | 中 | 可见的转让记录 | 中 | 委托专利律师审查 |
| 公开隐私政策 / 条款页面缺失 | 网站治理 / 法务合规 | 存在 | 中 | 低 | 可快速修复 | 低-中 | 确认正式政策和发布路径 |
排序依据是当前投资判断的重要性，而非法律技术细节。
[CR001, CR002, CR003, CR008, CR010, CR011]余下风险严重性主要来自获批、融资和准入。
[CR001, CR016, CR019, CR023, CR030, CR040]7.2 运营风险在于商业化系统不透明，而不是试验执行能力
公开证据支持 Biosplice 有能力运行复杂多中心研究，并维持外部科学参与。这是公司最清楚的运营强项。问题在于，这个强项覆盖开发，不一定覆盖上市。保留来源集没有让生产、CMC、 药物警戒、供应链或现场支持就绪度变得可读。对于后期生物技术公司，这个遗漏很重要，因为获批后的成功取决于公开材料中大多不可见的系统。因此，运营风险是不对称的： 公司看起来足以走到监管决策点，但同一公开记录不能证明它已准备好规模化商业化。这就是为什么获批本身无法清掉完整风险栈。正确的下一步尽调，是检查隐藏的运营机器， 而不是继续争论市场规模。实际问题是，公司是否已经完成了受控商业上市所需的那些不光鲜工作。[CR012, CR020, CR021, CR022, CR032, CR036]
| 失效模式 | 可能性 | 严重度 | 缓释成熟度 | 剩余暴露 | 未解决缺口 |
|---|---|---|---|---|---|
| CMC / 制造就绪度披露不足 | 中 | 高 | 低 | 高 | 无公开 CMC 细节 |
| 上市支持 / 药物警戒准备度不明 | 中 | 高 | 低 | 高 | 无公开支持系统清单 |
| 试验执行到商业化上市的衔接缺口 | 中 | 中 | 中 | 中-高 | 试验运营强，不等于上市运营已跑通 |
| 科学传播强于商业系统可见度 | 高 | 中 | 中 | 中 | 需要上市准备材料包 |
运营证据在研发阶段更强，商业化阶段仍弱。
[CR012, CR020, CR021, CR022, CR032, CR036]临床和监管风险会直接传导到现金、准入和估值。
[CR002, CR003, CR005, CR016, CR023, CR030]7.3 合作伙伴、客户准入和融资风险会相互叠加
Biosplice 的合作伙伴结构既帮忙，也制造风险。Haisco 和 Samil 通过显示外部交易对手愿意签下该资产，降低了商业化故事的孤立感。它们也制造集中度，因为具名伙伴只有少数几家， 客户故事仍处于商业化前阶段。若这些伙伴表现不佳，或支付方准入较弱，可见变现通道会迅速变窄。财务不透明会放大这个风险。Form D 活动和融资公告显示，公司反复接触资本， 但没有披露当前现金、烧钱速度或现金跑道。支撑较弱的 2026 年零售融资说法增加的是噪音，不是清晰度。合在一起看，伙伴依赖、支付方准入不确定性和融资不透明不是彼此独立的问题； 如果获批时点或上市牵引力令人失望，它们会相互强化。[CR013, CR015, CR016, CR017, CR018, CR019]
| 依赖项 | 交易对手 / 背景 | 角色 | 集中度 | 失效情景 | 严重度 | 缓释 | 剩余暴露 |
|---|---|---|---|---|---|---|---|
| 中国合作伙伴 | Haisco | 区域开发 / 商业化 | 高 | 执行或里程碑表现不及预期 | 高 | 合同权利和备选 BD 选项 | 高 |
| 韩国合作伙伴 | Samil | 区域开发 / 商业化 | 高 | 上市推进慢或市场建设弱 | 中-高 | 合同治理与支持 | 中-高 |
| 支付方准入 | CMS / 商业支付方 | 覆盖与采用关口 | 高 | 报销弱或编码延迟 | 高 | HEOR 与准入工作 | 高 |
| 资金提供方 | 私募投资者 | 现金跑道与稀释桥 | 高 | 延迟迫使公司在压力下融资 | 高 | NDA 若成功可降低风险 | 高 |
节奏一旦滑坡，合作伙伴依赖和融资依赖会相互放大。
[CR013, CR015, CR016, CR017, CR018, CR019]上市论点取决于监管方、资本、支付方和少数合作伙伴。
[CR015, CR016, CR019, CR025, CR026, CR027]7.4 在获批、准入和流动性更清晰前，剩余风险仍高
正确的剩余风险判断仍应保守。获批风险是一阶问题，但不是唯一一阶问题。准入和定价准备几乎同样重要，因为标签弱或报销慢，会掏空已获批药物的价值。现金不透明也是一阶风险， 因为它决定公司有多少时间吸收延迟。已终止的 SM08502 研究、肿瘤机构证明对 OA 上市关联有限等组合问题，不主导投资逻辑，但会影响管理层焦点和可选性。净结果是： Biosplice 应被视为一家拥有真实科学和战略上行空间、但执行栈集中且披露不足的公司。这正是明确否决标准和具体尽调追问比泛泛热情更重要的案例。 一次意外延迟就可能同时、系统性且严重地级联到融资、准入和合作伙伴信心。[CR006, CR007, CR014, CR023, CR029, CR030]
08估值
8.1 推荐与价格纪律
公开证据支持关注 Biosplice，而不是直接买入。公司仍有一个正当的后期资产、多项历史融资证明，以及愿意为 lorecivivint 支付有意义区域经济性的外部伙伴。这些事实都真实。 问题在于价格纪律。最可见的估值锚仍是 2018 年据报道 $12B 私募估值，以及少数二级市场或追踪页面；这些页面要么复用旧参考，要么依赖未披露模型， 要么明确标注其所有权数据为估计。与此同时，同一公开记录仍未披露当前现金、烧钱速度、股权结构表优先权、已实现伙伴收款、上市定价或支付方准备度。 这个错配比公司的出身更重要。纪律严明的委员会可以保持兴趣，同时拒绝把历史光环或追踪页面当作当前公允价值。正确姿态因此是继续研究 / 观察； 只有当私有证据补上估值和流动性缺口时，推荐才应上调。[CV002, CV003, CV006, CV007, CV008, CV009]
| 维度 | 评估 | 证据依据 | 决策含义 |
|---|---|---|---|
| 建议 | 继续研究 / 观察 | 后期资产属实，历史融资也有支撑，但当前估值依据仍然间接 | 不应仅凭公开记录买入 |
| 置信度 | 中低 | 融资历史和监管阶段佐证充分；当前定价证据不足 | IC 承诺前必须完成私下尽调 |
| 风险评级 | 高 | 获批、准入、现金跑道和条款不透明仍是一阶风险 | 严守价格和条款纪律 |
| 估值立场 | 偏高 / 支撑不足 | 跟踪页面把公司放在百亿美元级独角兽语境下，但缺少最新一级市场估值证明 | 锚定下行保护，而不是历史光环 |
| 上调触发条件 | 只凭证据推进 | 股权结构表、现金跑道、标签、准入和上市材料包必须通过尽调阈值 | 只有私下材料包足够强，才把兴趣转成买入 |
建议取决于价格和证据，不是泛泛给公司质量打分。
[CV002, CV003, CV009, CV022, CV023, CV024]| 论点 | 证据支撑 | 改变判断的证据 |
|---|---|---|
| 投资逻辑：lorecivivint 是真实的后期资产 | NDA 已提交，现有来源仍将其视为 NDA/BLA 阶段 | 实际获批、标签范围和上市计划 |
| 投资逻辑：外部合作伙伴验证了资产 | Haisco 和 Samil 披露了有意义的区域经济条款 | 合作伙伴经济条款能兑现成价值的证据 |
| 投资逻辑：历史融资能力异常强 | 2018 年据报道 $12B 估值，加上后续融资轮 | 当前条款和现金跑道，而不只是历史光环 |
| 反向逻辑：估值证据已经陈旧 | 跟踪页面依赖旧参考或不透明模型 | 已签署、包含当前定价和投资者保护的投资条款清单 |
| 反向逻辑：经济性不透明 | 无公开收入、利润率、烧钱速度或现金跑道数据 | 包含现金桥和商业化假设的私下财务材料包 |
| 反向逻辑：混合证据可能压低价格 | OA 证据不够干净，溢价倍数很难一路无阻 | 获批，加上报销进展和清晰的上市后指标 |
每个论点都配有可证伪的尽调问题，并非永久真理。
[CV001, CV002, CV014, CV015, CV016, CV021]投资判断从战略可信度出发，经由估值不透明，落到「继续研究」建议。
[CV001, CV014, CV015, CV031, CV032, CV039]面向 IC 的简洁指标显示战略可信度，但估值支撑偏弱。
[CV026, CV031, CV032, CV039, CV041, CV042]8.2 公开记录真正支撑什么，又只是指向什么
公开记录最强之处在于历史融资和当前战略阶段。MedCity、Tracxn、2021 年公司融资发布和 SEC 文件轨迹，让人很容易说 Biosplice 曾拥有异常高的私募估值， 并在更名后又募集了更多资本。Synapse 和 NDA 公告也让人同样容易说，主导资产已达到严肃监管里程碑。公开记录不支撑的，是把这些事实连续延伸到今天价格。 UpMarket、Notice、Dealroom、Seedtable 和相关追踪网站是有用的定位工具，但不能替代已签投资条款清单或经审计财务包。它们在融资轮、投资人或估值方法上的分歧不是致命问题； 只是说明本章为什么必须基于情景。一章估值若假装这些页面是第一手证据，就会夸大确定性。更诚实的看法是：Biosplice 战略上可信，但仍通过一面不透明的私募市场镜子被定价。[CV001, CV002, CV004, CV005, CV006, CV007]
| 可比对象 | 指标 | 倍数 / 估值 / 状态 | 相关性 | 局限 |
|---|---|---|---|---|
| Biosplice 2018 年私募轮 | 历史融资估值 | 据报道，$438M 轮融资投前估值 $12B | 最知名的历史估值锚 | 已陈旧且发生在 NDA 前；不是当前公允价值 |
| Biosplice 2021 年融资 | 后续私募融资 | 公司宣布 $120M 融资；估值未披露 | 显示更名后仍有融资能力 | 未披露投后估值或优先权条款 |
| UpMarket / Notice 跟踪页面背景 | 类老股的私募市场信号 | UpMarket 引用 $12.44B 参考值和 $11B 估计值；Notice 显示 $4.87 股价标题 | 有助于理解当前市场叙事和流动性框架 | 模型驱动、间接，也不是定价轮 |
| Lorecivivint 中国授权 | 适合估值模型的交易参考 | 总价值最高 $140M，包含首付款和里程碑 | 锚定外部对区域权益的真实支付意愿 | 不是企业股权估值 |
| Lorecivivint 韩国授权 | 适合估值模型的交易参考 | 总价值最高 $70M | 增加第二个外部资产价值参考 | 仍不是企业股权估值 |
| Caplight / VentureRadar / Tracxn 的同业篮子 | 基于相似度的可比组 | OrthoTrophix、Kolon TissueGene、Eupraxia、Surrozen、Skyhawk、Frequency、Arrakis 等出现在类比对象中 | 有助于同业框架和类别定位 | 抓取摘录未提供干净的匹配倍数组合 |
这只是估值相关参考的样本列举，不是完整或标准化的公开可比公司表。
[CV002, CV003, CV007, CV008, CV012, CV013]公开估值参考横跨小额合作交易、累计融资额和很高的追踪器估值标记。
这些数字混合了交易价值、累计融资额和追踪器式估值参考；放在一起是为了展示公开锚点跨度有多宽，不暗示它们可以等同看待。
[CV002, CV003, CV005, CV007, CV014, CV015]8.3 情景和可比公司应用来框定估值，而不是假装解出估值
同业集合有助于给讨论划边界，但不会给出整齐的表格答案。Caplight、VentureRadar 和 Tracxn 把 Biosplice 归到再生医学、RNA 和专科生物技术同业旁边，而不是一组可直接对标的上市公司。这在方向上有用，因为它显示投资人和数据库如何给公司分类；但还不足以支撑直接套倍数。更相关的投资判断参照是历史融资估值、Haisco 和 Samil 交易价值、后期 NDA 里程碑，以及平台可选性与当前商业化不透明之间的落差。乐观情景需要获批、报销可行，且当前融资条款不会把新资本卡在旧私募估值之后。基准情景假设科学与合作叙事仍可信，但价格必须回落到当前披露能支撑的水平。悲观情景假设获批时间推迟、支付方准入弱于预期，或公司必须在压力下融资。这些结果本来就会拉出很宽的估值区间。[CV012, CV013, CV014, CV015, CV016, CV018]
| 情景 | 假设 | 估值 / 回报逻辑 | 概率信号 | 下行触发因素 |
|---|---|---|---|---|
| 乐观 | 获批落地，标签具备商业可用性，准入工作可信，股权结构条款普通 | 若上市快速降低风险，以低于陈旧百亿美元级独角兽预期的受保护价格进入，回报有复利空间 | 私下材料包确认现金跑道和上市准备度 | 获批延迟、标签不利或优先股堆叠 |
| 基准 | 科学与合作伙伴叙事仍可信，但公开指标仍不完整 | 观察或尽调后持有；价格应重置到当前披露能支撑的水平 | 历史融资加合作伙伴经济条款保住期权价值 | 无法进入数据室，或缺乏估值纪律 |
| 悲观 | 获批、准入或融资出问题，而当前估值仍锚定旧光环 | 平轮或降价轮的可能性上升，上行空间收窄 | 老股流动性仍弱，条款对投资者不友好 | 被迫融资或报销乏力 |
情景逻辑只给方向，不给精确数值，因为公开证据不足以支撑干净的 DCF 或 收入倍数模型。
[CV016, CV021, CV023, CV024, CV025, CV033]公开证据支持的是很宽的情景区间，而不是单一公允价值点。
这些情景区间是与获批、准入、稀释和披露结果挂钩的投资测算启发式假设；它们不是公司指引，也不是市场报价。
[CV033, CV034, CV035, CV037, CV038, CV039]8.4 最终判断应看私有披露，而不是更多叙事
眼下最有价值的工作不是再做一份泛泛的市场调查，而是私有尽调。决定性要项很直接：当前投后估值和持股、清算优先权、期权池扩张、当前现金和烧钱速度、董事会现金跑道计划、获批标签情景、报销假设、上市准备证据，以及区域交易经济条款确实转化为战略杠杆、而不是停留在旧新闻稿标题里的证明。如果这些材料显示条款常规、现金跑道足够，并且公司在显著更低或保护更好的入场点上具备可信的商业化准备，建议可以很快上调。如果材料显示压力、优先股堆叠或流动性单薄，投资逻辑也应同样快地失效。因此 Biosplice 是一个价格敏感的继续研究案例，而不是永久放弃。公开证据说明它值得尽调；但还没有公开记录基础可以支持按十角兽式估值买入。[CV021, CV022, CV023, CV024, CV028, CV032]
| 触发因素 | 阈值 | 对投资逻辑的传导 | 行动含义 |
|---|---|---|---|
| 获批或标签不及预期 | 出现实质延迟，或标签范围窄于商业计划要求 | 削弱核心价值驱动，并拉长融资风险 | 暂停投资，或要求重新定价的条款 |
| 现金或现金跑道偏弱 | 现金跑道不足以吸收上市或监管延误 | 把估值讨论推向稀释保护，而不是上行空间 | 要求过桥方案，否则退出 |
| 优先权包袱 | 优先股堆叠、激进强制跟投条款，或大规模期权池重置 | 可能抹掉新投资者的表面上行空间 | 重新定价或拒绝 |
| 报销计划偏弱 | 没有可信的编码、准入或 HEOR 策略 | 让获批药物变成慢启动或低价值上市 | 等到准入证据出现后再承诺 |
| 合作伙伴表现不及预期 | 区域合作伙伴执行失败，或经济条款价值低于宣传 | 压缩可选性，并削弱外部验证 | 下调情景权重和估值区间 |
终止标准刻意做成可监测，并绑定可用于投资判断的事件。
[CV016, CV022, CV023, CV024, CV033, CV035]| 主题 | 缺失证据 | 为什么重要 | 负责人或尽调路径 |
|---|---|---|---|
| 当前估值与条款 | 已签投资条款清单、当前投后估值、清算优先权、期权池计划 | 把数据库叙事转成真实入场价格测算 | 领投方律师 + CFO 尽调 |
| 流动性与现金跑道 | 当前现金、烧钱速度、现金跑道桥接和下行情景模型 | 判断延误是否会逼出被动融资 | 董事会材料与 CFO 审阅 |
| 商业化假设 | 上市价格区间、报销计划和准入里程碑 | 把获批转成收入价值所必需 | 商业负责人 + 市场准入审阅 |
| 上市准备度 | CMC、供应链、医学事务和药物警戒包 | 即便获批，运营准备不足也会毁掉股权价值 | 质量 / 监管尽调 |
| 合作伙伴价值兑现 | Haisco 和 Samil 里程碑状态、收款、修订和治理 | 判断披露交易金额是否构成真实经济支撑 | BD / 法务尽调 |
要提高投资建议，最快路径不是再截更多公开数据库截图，而是拿到更好的私有证据。
[CV014, CV015, CV022, CV023, CV024, CV032]免责声明
截至 2026-08-18，本报告只是基于公开来源的尽调辅助材料，不构成投资建议。Biosplice 当前估值、资本结构和经营指标仍未公开；凡是挂钩历史估值标记或追踪页面的数字，在一手交易和财务材料确认前，都只能作为方向性背景。
证据索引
| 编号 | 陈述 | 可信度 | 来源 |
|---|---|---|---|
| CO001 | Biosplice Therapeutics is a private clinical-stage biotechnology company headquartered in San Diego, California. | 中 | SO002, SO001 |
| CO002 | Dealroom dates Biosplice's founding to 2008. | 中 | SO023 |
| CO003 | Biosplice focuses on first-in-class small-molecule therapeutics linked to CLK/DYRK kinase modulation and alternative RNA splicing. | 中 | SO001, SO007, SO016 |
| CO004 | Public materials position lorecivivint for knee osteoarthritis as Biosplice's lead program. | 中 | SO001, SO007, SO009 |
| CO005 | Current public management materials name Erich Horsley as chief executive officer. | 中 | SO004, SO005 |
| CO006 | Current public management materials name Osman Kibar as founder and executive chairman. | 中 | SO004, SO005, SO024 |
| CO007 | Current public management materials name Yusuf Yazici as chief medical officer. | 中 | SO004, SO024 |
| CO008 | Current public management materials name Phil Wilson as chief financial officer. | 中 | SO004, SO024 |
| CO009 | Current public management materials name Scott W. Bulcao as chief legal officer. | 中 | SO004, SO024 |
| CO010 | The public board page lists Finian Tan of Vickers Venture Partners as a director. | 中 | SO005 |
| CO011 | The public board page lists Stephen Zachary of Sands Capital as a director. | 中 | SO005 |
| CO012 | The public board page lists Ahmed Khizer Khan of Daman Investments as a director or board advisor. | 中 | SO005 |
| CO013 | Biosplice announced a $120 million equity financing on April 15, 2021. | 中 | SO016, SO021 |
| CO014 | Biosplice said the 2021 financing proceeds would support lorecivivint plus oncology and neurology programs. | 中 | SO016 |
| CO015 | The 2021 financing announcement identified Eventide, aMoon, SymBiosis II, Sands Capital, and Verition among new investors. | 中 | SO016, SO026 |
| CO016 | The SEC shows BioSplice Therapeutics filed a Form D on March 3, 2021. | 中 | SO021, SO020 |
| CO017 | The SEC shows BioSplice Therapeutics filed another Form D on August 24, 2022. | 中 | SO022, SO020 |
| CO018 | Biosplice licensed China development and commercialization rights for lorecivivint to Haisco in September 2021. | 中 | SO013, SO014 |
| CO019 | Biosplice said the Haisco transaction carried $140 million of aggregate value including $20 million of upfront payment and early development milestones. | 中 | SO013, SO014 |
| CO020 | Biosplice also licensed Korean rights for lorecivivint to Samil in 2021. | 中 | SO015 |
| CO021 | In November 2022 Biosplice reported that earlier phase 3 trials OA-10 and OA-11 missed their primary 12-week pain endpoint in all-comers. | 中 | SO012 |
| CO022 | The same 2022 announcement said OA-07 showed structural and pain signals that informed the design of OA-21. | 中 | SO012 |
| CO023 | Biosplice said it discussed OA-21 with FDA in the third quarter of 2022 before planned enrollment. | 中 | SO012 |
| CO024 | In November 2023 Biosplice presented OA-07 extension results showing structure benefit and symptomatic benefit over multiple annual injections. | 中 | SO011 |
| CO025 | The 2023 OA-07 release reported a 0.15 mm advantage versus the last observed placebo comparison and 0.26 mm versus extrapolated placebo progression at 36 months. | 中 | SO011 |
| CO026 | In April 2024 Biosplice disclosed that OA-21 did not meet its 12-week primary endpoint for pain reduction. | 中 | SO010 |
| CO027 | The April 2024 release nevertheless said OA-07 final analysis confirmed statistically significant pain, function, and structural benefit. | 中 | SO010 |
| CO028 | In January 2026 Biosplice announced submission of a new drug application for lorecivivint to FDA. | 中 | SO009, SO017, SO018 |
| CO029 | The January 2026 NDA announcement said lorecivivint had been evaluated in 11 clinical trials and in more than 1,800 dosed patients. | 中 | SO009, SO018 |
| CO030 | Drugs.com still described lorecivivint as investigational and not FDA approved as of the research date. | 中 | SO018 |
| CO031 | ClinicalTrials.gov search results show Biosplice-sponsored studies spanning osteoarthritis, hair loss, and oncology indications. | 中 | SO019, SO030 |
| CO032 | The Synapse organization overview describes Biosplice as having pipeline activity across osteoarthritis, cancer, diabetes, traumatic brain injury, and other degenerative conditions. | 中 | SO030 |
| CO033 | Dealroom labels Biosplice a San Diego biotech founded in 2008 and describes it as medical research and development for tissue-level regeneration. | 中 | SO023 |
| CO034 | Seedtable lists five current executives and three public board members on its public Biosplice profile. | 中 | SO024 |
| CO035 | Caplight publicly shows Biosplice funding-round entries for April 2016, August 2018, and April 2021. | 中 | SO025 |
| CO036 | Dealroom, Caplight, and other trackers preserve Biosplice's 2018-era decacorn narrative but do not provide a fresh public price discovery event after 2021. | 中 | SO023, SO025, SO027 |
| CO037 | The careers page shows no open job postings at the time of review. | 中 | SO003 |
| CO038 | The careers page and public contact materials point to a single San Diego headquarters and do not substantiate a broad multi-office operating footprint. | 中 | SO003, SO002 |
| CO039 | The 2026 retail-investor fundraising narrative is supported only by low-reputation third-party coverage and is not confirmed on Biosplice's official news page. | 低 | SO028, SO008 |
| CO040 | UpMarket shows a live private-market profile for Biosplice shares aimed at accredited investors, indicating at least some secondary-market interest. | 低 | SO027 |
| CO041 | SymBiosis presents Biosplice as a portfolio company, corroborating its presence in specialist biotech investor networks. | 中 | SO029 |
| CO042 | No official Biosplice press release or SEC filing in the reviewed set publicly confirms a 2026 $500 million-plus retail raise. | 低 | SO008, SO020 |
| CM001 | Biosplice is not pursuing the whole arthritis market; its near-term commercial focus is knee osteoarthritis treated by injection rather than systemic arthritis care. | 中 | SM001, SM002, SM013 |
| CM002 | The company frames lorecivivint as a potential disease-modifying osteoarthritis therapy rather than a short-duration analgesic. | 中 | SM001, SM002 |
| CM003 | The Biosplice osteoarthritis page cites roughly 51.9 million U.S. adults and 527.8 million adults globally with osteoarthritis. | 中 | SM001 |
| CM004 | The January 2026 NDA release cites roughly 50 million U.S. adults and over 500 million adults globally with osteoarthritis. | 中 | SM002, SM024 |
| CM005 | The Biosplice osteoarthritis page cites about 24.7 million U.S. adults with knee osteoarthritis. | 中 | SM001 |
| CM006 | The January 2026 NDA release cites about 25 million Americans with knee osteoarthritis. | 中 | SM002 |
| CM007 | The Global Burden of Disease 2021 analysis projects continued growth in osteoarthritis prevalence through 2050. | 中 | SM007 |
| CM008 | CDC FastStats and NIAMS both describe arthritis and osteoarthritis as large and durable public-health burdens in the United States. | 中 | SM005, SM006 |
| CM009 | OARSI characterizes osteoarthritis as a serious disease rather than a minor quality-of-life condition. | 中 | SM008, SM002 |
| CM010 | NICE guidance places exercise, weight management, analgesia, injections, and surgery on the treatment pathway before a novel DMOAD would become routine care. | 中 | SM013, SM014 |
| CM011 | Arthritis Foundation and NIAMS materials show that OA care is still organized around symptom management and function preservation rather than disease reversal. | 中 | SM012, SM006 |
| CM012 | ClinicalTrials.gov and company materials show Biosplice repeatedly emphasizing earlier-stage KL2 and early KL3 patients as the subgroup with the clearest signal. | 中 | SM004, SM010 |
| CM013 | The 2022 Biosplice release said earlier, less structurally damaged patients represented roughly 70% of the knee OA population studied by the company. | 中 | SM004 |
| CM014 | If the 25 million U.S. knee OA figure and the 70% earlier-stage subgroup assumption are both directionally correct, the company's preferred subgroup implies a candidate population around 17.5 million people before payer and contraindication filters. | 中 | SM002, SM004 |
| CM015 | The main user of lorecivivint would be the injecting clinician, while the buyer and payer functions would sit with health systems and insurers rather than the patient alone. | 中 | SM013, SM014, SM011 |
| CM016 | The once- or twice-yearly intra-articular delivery model implies adoption through orthopedics, sports medicine, and rheumatology workflows rather than retail pharmacy self-administration. | 中 | SM001, SM011, SM023 |
| CM017 | Zilretta, Synvisc-One, Monovisc, and Durolane exemplify the incumbent non-surgical injection set lorecivivint must displace or sit alongside. | 中 | SM015, SM017, SM019, SM021 |
| CM018 | Pacira positions Zilretta around OA knee pain relief rather than structure modification. | 中 | SM015, SM016 |
| CM019 | Synvisc-One and Monovisc are positioned as viscosupplement injections, again emphasizing symptom relief and mobility rather than disease modification. | 中 | SM017, SM018, SM019, SM020 |
| CM020 | Biosplice's market thesis depends on convincing payers and clinicians that a structure-modifying product deserves adoption despite a treatment pathway already crowded with symptom-focused injections and conservative care. | 中 | SM001, SM013, SM017, SM015 |
| CM021 | The April 2024 release disclosed that OA-21 did not meet its 12-week primary endpoint for pain reduction, underscoring that placebo response and endpoint selection remain commercial as well as clinical constraints. | 中 | SM003 |
| CM022 | The 2022 release similarly acknowledged that OA-10 and OA-11 fell short on their primary all-comer pain endpoints even while subgroup signals looked better. | 中 | SM004 |
| CM023 | The 2026 NDA filing means Biosplice has progressed farther than most OA drug developers, but FDA approval remained pending at the research date. | 中 | SM002, SM011 |
| CM024 | Public evidence supports multiple prevalence lenses, but not a single clean public SAM or SOM in annual dollar terms. | 中 | SM007, SM005, SM013 |
| CM025 | ClinicalTrials.gov shows a substantial development footprint around lorecivivint, which helps validate market seriousness even if it does not prove payer acceptance. | 中 | SM009, SM010 |
| CM026 | The OA-11 study record confirms that Biosplice tested a phase 3 population of 40-80 year old adults with symptomatic knee OA, reinforcing that the commercial target lies within a common older-adult chronic-disease workflow. | 中 | SM010 |
| CM027 | Arthritis Foundation and NIAMS both present osteoarthritis as chronic, mobility-limiting, and highly prevalent, supporting durable long-term demand if an effective therapy clears the evidence bar. | 中 | SM012, SM006 |
| CM028 | NICE and NCBI guidance imply that any premium-priced new injection would need to prove superiority or meaningful differentiation against conservative management and incumbent injectables. | 中 | SM013, SM014, SM015 |
| CM029 | The ACR on Air episode centered on lorecivivint publications indicates at least some rheumatology-community attention, but not yet broad real-world adoption proof. | 中 | SM023, SM003 |
| CM030 | Broad analyst dollar-TAM narratives are weaker than prevalence-led market sizing because public sources disagree on exactly which spending categories belong inside the addressable market. | 中 | SM013, SM006, SM011 |
| CM031 | The market chapter should therefore treat prevalence and workflow penetration as the primary sizing logic and preserve dollar-SAM uncertainty as an explicit diligence gap. | 中 | SM007, SM013, SM011 |
| CM032 | Global OA burden can be framed at roughly 500 million-plus adults, U.S. OA burden at roughly 50 million-plus adults, and U.S. knee OA burden at roughly 25 million adults. | 中 | SM001, SM002, SM007 |
| CM033 | The addressable care path excludes rheumatoid arthritis biologics, general orthopedic hardware, and unrelated chronic-pain spend. | 中 | SM013, SM006 |
| CM034 | Payers remain crucial because guideline placement and reimbursement determine whether a novel injection reaches routine use beyond specialty centers. | 中 | SM013, SM011 |
| CM035 | Status-quo substitutes include exercise and weight management, oral or topical analgesics, steroid injections, hyaluronic-acid injections, and eventual arthroplasty. | 中 | SM013, SM006, SM017, SM015 |
| CM036 | A key adoption constraint is that the market already tolerates lower-evidence symptomatic care, which can make premium reimbursement for a novel agent difficult even when unmet need is real. | 中 | SM013, SM011, SM012 |
| CM037 | A key growth driver is the combination of aging populations, obesity-linked joint damage, and a lack of approved disease-modifying OA drugs. | 中 | SM007, SM006, SM008 |
| CM038 | Biosplice's commercial story is strongest if regulators and payers accept structure plus symptom benefit as a materially better proposition than incumbent pain-focused injections. | 中 | SM002, SM003, SM015, SM017 |
| CM039 | Public evidence does not yet quantify real-world physician uptake, payer coverage, or price elasticity for lorecivivint because the product remains unapproved. | 中 | SM011, SM002 |
| CM040 | Because the product remains unapproved, the practical SOM today is zero realized commercial patients even though the candidate population could be large. | 中 | SM011, SM002 |
| CM041 | No reviewed primary public source provides a clean, company-specific annual revenue TAM for Biosplice's knee OA opportunity. | 中 | SM013, SM007, SM006 |
| CP001 | Public evidence still shows no approved disease-modifying osteoarthritis drug, so Biosplice competes mainly against symptom-focused incumbents and surgical deferral pathways rather than a like-for-like DMOAD peer. | 高 | SP001, SP002, SP019 |
| CP002 | Zilretta is positioned around osteoarthritis knee pain relief as an extended-release corticosteroid, not around structural modification. | 中 | SP007, SP008 |
| CP003 | Synvisc-One, Monovisc, Orthovisc, Euflexxa, and Hyalgan are all marketed as hyaluronic-acid or sodium-hyaluronate injections for knee-OA pain relief. | 高 | SP009, SP011, SP014, SP015, SP016 |
| CP004 | Cingal combines hyaluronic acid with steroid, showing that incumbents already experiment with convenience-plus-speed positioning even without claiming disease modification. | 中 | SP017 |
| CP005 | AAOS and OrthoInfo materials show that conservative care and eventual total knee replacement remain important substitutes around any new injectable therapy. | 高 | SP019, SP018 |
| CP006 | OrthoInfo says more than 700,000 total knee replacements are performed annually in the United States, underscoring the scale of the downstream substitute pathway. | 中 | SP018 |
| CP007 | Biosplice attempts to differentiate lorecivivint by arguing for both pain/function benefit and structural benefit, which is a different message from incumbent injection brands. | 中 | SP001, SP002, SP003 |
| CP008 | That differentiation story is weakened by Biosplice's own disclosure that OA-21 missed its 12-week primary pain endpoint. | 中 | SP003 |
| CP009 | The 2022 company release also acknowledged mixed all-comer outcomes in OA-10 and OA-11, which means Biosplice is not entering the market with an unambiguously superior clinical record. | 高 | SP004, SP006 |
| CP010 | Because lorecivivint remained pending at the FDA as of the research date, incumbent products still own the trust, coding familiarity, and routine-office workflow advantages. | 中 | SP002, SP007, SP009, SP015 |
| CP011 | Monovisc and Orthovisc materials show Anika products competing on dosing convenience and clinical familiarity, while J&J MedTech helps distribute Monovisc and the Orthovisc page says its U.S. syringe is distributed exclusively by J&J MedTech. | 中 | SP011, SP012, SP014 |
| CP012 | Euflexxa explicitly advertises Medicare Part B coverage without restrictions, signaling that reimbursement familiarity is already part of incumbent positioning. | 中 | SP015 |
| CP013 | Orthovisc claims over 21 million injections worldwide, an adoption signal that newcomer Biosplice cannot yet match commercially. | 中 | SP014 |
| CP014 | Hyalgan presents decades of studies and approval history, illustrating how legacy products can compete on longevity and familiarity rather than innovation. | 中 | SP016 |
| CP015 | The practical buying job is therefore not only efficacy selection but also choosing between familiar reimbursed pain-relief tools and an unproven new category. | 中 | SP015, SP007, SP002 |
| CP016 | Biosplice does not need to displace total knee replacement for all patients; it more plausibly needs to become an earlier escalation step for patients trying to delay surgery. | 中 | SP001, SP018, SP002 |
| CP017 | Switching costs arise from physician habit, payer prior-authorization logic, injection procedure workflows, and the absence of public price transparency for many incumbents. | 中 | SP019, SP015, SP009 |
| CP018 | Public competitor pages emphasize packaging and regimen differences: single injection for products like Monovisc and Synvisc-One versus multi-injection regimens for Orthovisc and Euflexxa/Hyalgan. | 高 | SP011, SP009, SP014, SP015, SP016 |
| CP019 | Those packaging differences matter because a novel product can win on convenience even before it wins on health-economic proof. | 中 | SP011, SP014, SP017 |
| CP020 | Publicly reviewed competitor sources rarely provide reliable net pricing, which limits any precise price-to-value comparison in this chapter. | 中 | SP007, SP009, SP015, SP016 |
| CP021 | The chapter should therefore treat dosing, indication framing, and channel familiarity as better-supported comparison axes than absolute list price. | 中 | SP011, SP014, SP015 |
| CP022 | ClinicalTrials.gov shows Biosplice is also advancing oncology splicing programs, including SM04755 and cirtuvivint studies, so the company is strategically broader than a single OA asset. | 中 | SP020, SP022, SP023 |
| CP023 | The SM08502 combination study was terminated for business reasons, which is an adverse signal that portfolio focus and capital allocation can shift. | 中 | SP021 |
| CP024 | The AML/MDS cirtuvivint study remained active and Biospace reported first patient dosing in an NCI-sponsored trial, which supports ongoing oncology optionality rather than abandonment. | 中 | SP022, SP023, SP024 |
| CP025 | That optionality is double-edged for OA investors: it can diversify platform value, but it can also divide leadership attention and capital while lorecivivint still needs launch execution. | 中 | SP021, SP022, SP002 |
| CP026 | DrugPatentWatch adds only weak public proof on lorecivivint IP and should be treated as a low-confidence pointer rather than a moat conclusion. | 低 | SP025 |
| CP027 | If approval lands, Biosplice's moat would come primarily from differentiated clinical claims and first-mover status in a new category, not from an already-entrenched commercial channel. | 中 | SP002, SP003, SP019 |
| CP028 | If approval slips or the label is narrow, incumbents with familiar reimbursement and office workflows could blunt that moat quickly. | 中 | SP002, SP003, SP015, SP011 |
| CP029 | Existing vendor-authored comparison surfaces are useful for packaging facts but not independent proof of superiority, so unsupported cells in the matrix should remain explicitly unknown. | 中 | SP007, SP009, SP014 |
| CP030 | The most defensible direct-competition framing is: incumbents for pain relief, surgery for downstream substitution, and no approved direct DMOAD peer yet. | 中 | SP007, SP009, SP018, SP002 |
| CP031 | Incumbent categories split into corticosteroid, hyaluronic-acid, HA-plus-steroid combo, conservative-care substitutes, and surgery. | 中 | SP007, SP009, SP017, SP019, SP018 |
| CP032 | Biosplice's chief advantage claim is disease-modification potential, while its chief disadvantage is lack of approved commercial proof. | 中 | SP001, SP002, SP003 |
| CP033 | Competitor channel power is strongest where products are already integrated into specialist injection workflows and payer coverage precedents. | 中 | SP015, SP012, SP008 |
| CP034 | Single-injection incumbents may be closer analogs for convenience comparison, while multi-injection incumbents highlight follow-up burden and workflow stickiness. | 中 | SP011, SP009, SP014, SP016 |
| CP035 | Biosplice's oncology pipeline broadens the company profile but does not directly solve the knee-OA treatment job, so it belongs in strategic-direction context rather than the direct-rival set. | 中 | SP020, SP022, SP002 |
| CP036 | The most serious displacement risks are clinical underperformance, narrow label scope, payer resistance, and a quick incumbent response on convenience or contracting. | 中 | SP003, SP015, SP011 |
| CP037 | No reviewed source proves robust clinician multi-homing shares across products, so market-share style switching estimates should remain out of scope. | 中 | SP009, SP014, SP015 |
| CP038 | Because public pricing data are thin, competitive readiness is better scored on approval status, indication fit, dosing convenience, and reimbursement familiarity. | 中 | SP002, SP015, SP011, SP014 |
| CP039 | On balance, Biosplice looks differentiated on thesis but weaker than incumbents on trust, reimbursement familiarity, and demonstrated commercial durability. | 中 | SP002, SP003, SP015, SP014 |
| CI001 | Public sources still support a pre-revenue commercial profile: lorecivivint remained unapproved at the research date and no product sales are disclosed. | 高 | SI001, SI017, SI018 |
| CI002 | The clearest public monetization lanes are partnership economics, not recognized product revenue. | 中 | SI003, SI004, SI012 |
| CI003 | Biosplice's Haisco transaction was described as up to $140 million including $20 million in upfront and early development milestones. | 高 | SI003, SI012, SI011 |
| CI004 | Biosplice's Samil transaction was described as up to $70 million in aggregate value for Korea rights. | 高 | SI004, SI013, SI015 |
| CI005 | Those partnership figures describe contingent deal value, not necessarily realized cash receipts or recognized revenue. | 中 | SI003, SI004, SI012 |
| CI006 | The April 2021 company financing release said Biosplice closed $120 million in equity financing to advance clinical programs. | 中 | SI002 |
| CI007 | The 2021 and 2022 Form D filings corroborate that Biosplice continued to use private-placement financing instruments, but do not supply an audited cash balance or burn schedule. | 高 | SI005, SI006 |
| CI008 | The 2018 Samumed Form D filing underscores that the company has relied on private capital formation for years before the Biosplice rebrand. | 中 | SI007 |
| CI009 | Because the lead OA asset is only now at NDA review, forward revenue remains highly dependent on regulatory approval, label scope, reimbursement, and launch execution. | 中 | SI001, SI016, SI019, SI020 |
| CI010 | Public sources do not provide a credible launch price or contract model for lorecivivint today. | 中 | SI001, SI018 |
| CI011 | For an unapproved biotech product, classic SaaS-style sales-efficiency metrics such as CAC or payback are not supportable from public evidence. | 中 | SI001, SI003 |
| CI012 | The most defensible GTM proxy is partner geography and licensing structure rather than customer acquisition efficiency. | 中 | SI003, SI004 |
| CI013 | Ex-US monetization is visible through China and Korea licensing, while U.S. commercialization economics remain mostly undisclosed. | 中 | SI003, SI004, SI012 |
| CI014 | The public cost structure almost certainly includes clinical development, regulatory work, and pre-launch manufacturing scale-up, but audited expense lines are not disclosed in the retained sources. | 中 | SI001, SI019, SI002 |
| CI015 | Gross margin, COGS, inventory build, and working-capital requirements are all effectively private-evidence-only at this stage. | 中 | SI001, SI018 |
| CI016 | The clearest public capital-adequacy conclusion is not that Biosplice is fully funded, but that it has historically needed repeated external financing to keep multi-year clinical programs moving. | 高 | SI002, SI005, SI006, SI007 |
| CI017 | The NDA filing may improve financing leverage, but it does not itself prove sufficient cash to complete launch preparations. | 中 | SI001, SI016, SI002 |
| CI018 | Notice presents a secondary-market style stock price and valuation context, but this is not equivalent to audited intrinsic value or a new priced financing round. | 中 | SI008 |
| CI019 | Private-market tracker pages such as UpMarket, Caplight, Dealroom, and Seedtable are useful context but are too indirect to substitute for current audited financial statements. | 中 | SI021, SI022, SI023, SI024 |
| CI020 | The PlainPatent and Justia records show that Biosplice has a real patent asset base, but patent volume does not solve current cash-opacity or near-term margin questions. | 中 | SI009, SI010 |
| CI021 | The reported 2026 retail-investor raise remains weakly supported relative to official company and filing evidence and should not be treated as a verified cash source. | 中 | SI025, SI001, SI006 |
| CI022 | No retained public source quantifies realized royalties, milestone receipts, or deferred-revenue accounting from Haisco or Samil. | 中 | SI003, SI004, SI013 |
| CI023 | No retained public source quantifies monthly burn, runway months, or cash on hand. | 中 | SI005, SI006, SI002 |
| CI024 | No retained public source quantifies launch pricing, gross-to-net assumptions, or reimbursement economics for lorecivivint. | 中 | SI001, SI008 |
| CI025 | The financial chapter can support a partnership-led monetization model and a financing-dependent operating model, but not a precise near-term revenue forecast. | 中 | SI003, SI004, SI005, SI001 |
| CI026 | In financial terms, Biosplice looks like a late-stage biotech whose value is driven by approval probability and licensing optionality rather than present operating cash generation. | 中 | SI001, SI003, SI004, SI008 |
| CI027 | Public monetization categories are U.S. future product sales, ex-US licensing economics, and possible milestones or royalties. | 中 | SI001, SI003, SI004 |
| CI028 | Public pricing visibility today is effectively zero for realized lorecivivint economics. | 中 | SI001, SI008 |
| CI029 | Capital intensity is elevated because Biosplice has advanced a long clinical program and still faces regulatory-review and launch-preparation costs. | 中 | SI002, SI019, SI020 |
| CI030 | The company overview funding chronology is directionally useful, but financial underwriting still needs current cash, burn, and preference-stack documents. | 中 | SI005, SI006, SI008 |
| CI031 | Because there are no product-sales disclosures, every public financial scenario should be labeled estimated or unavailable rather than precise. | 中 | SI001, SI008, SI021 |
| CI032 | Licensing announcements provide geographic and headline-value clues but no recognized-revenue waterfall. | 中 | SI003, SI004, SI011 |
| CI033 | If approval lands, the most likely first visible economics are milestone, launch-investment, and pricing disclosures rather than immediate high-quality recurring revenue. | 中 | SI001, SI016, SI003 |
| CI034 | Secondary-market and tracker pages may indicate investor interest, but none of them eliminate the need for audited financial statements and current cap-table data. | 中 | SI008, SI022, SI023, SI024 |
| CI035 | The current public record is sufficient to call Biosplice capital intensive and financing dependent, but insufficient to call it well capitalized. | 中 | SI002, SI005, SI006, SI001 |
| CI036 | Overall financial quality is constrained less by lack of strategic ambition than by lack of current audited operating metrics. | 中 | SI005, SI001, SI008 |
| CE001 | Biosplice's lead delivered product is a healthcare-professional-administered intra-articular injection of lorecivivint for knee osteoarthritis. | 高 | SE001, SE018, SE019 |
| CE002 | ClinicalTrials.gov records show the OA program converged on a single 0.07 mg lorecivivint dose delivered in 2 mL vehicle for late-stage trials. | 高 | SE018, SE019 |
| CE003 | Earlier phase 2 studies explored multiple dose arms before the company narrowed onto the 0.07 mg dose. | 高 | SE016, SE017, SE023 |
| CE004 | Public Biosplice materials describe lorecivivint as a small-molecule CLK2/DYRK1A inhibitor and Wnt pathway modulator. | 高 | SE009, SE023, SE025 |
| CE005 | The product workflow is local joint injection rather than chronic systemic administration, which shapes both convenience and safety positioning. | 中 | SE001, SE016, SE018 |
| CE006 | The phase 2b OA paper reported efficacy on patient-reported outcomes and identified 0.07 mg as the lowest effective dose for future studies. | 高 | SE023, SE003 |
| CE007 | Phase 2a and phase 2b materials emphasize both pain/function outcomes and radiographic measures such as medial joint space width, showing that the product story blends symptom and structure claims. | 高 | SE005, SE016, SE023 |
| CE008 | STRIDES-1 prioritized patient-reported pain at Week 12, while STRIDES-X-ray emphasized radiographic structure alongside pain and function measures. | 高 | SE018, SE019 |
| CE009 | Biosplice's own later releases show that the program's maturity is meaningful but not cleanly linear, because mixed phase 3 pain results sat alongside longer-term structural claims. | 中 | SE006, SE007, SE008 |
| CE010 | The January 2026 NDA filing marks a product-stage transition from clinical development to regulatory review for lorecivivint. | 中 | SE008 |
| CE011 | The public asset map also includes oncology splicing programs such as SM04755 and cirtuvivint, making the platform broader than one OA asset. | 中 | SE002, SE020, SE022 |
| CE012 | The SM08502 combination study adds another oncology asset to the public pipeline even though that specific study was later terminated for business reasons. | 中 | SE021 |
| CE013 | The active NCT06484062 AML/MDS study indicates the company still advances cirtuvivint in hematologic malignancy with NCI-linked support. | 中 | SE022 |
| CE014 | The public operating model in OA depends on broad multicenter trial execution across many U.S. sites rather than bespoke hospital deployment. | 中 | SE017, SE018, SE019 |
| CE015 | That site-network dependence means operational readiness is partly a trial-operations and evidence-package problem, not purely a molecule-design problem. | 中 | SE017, SE018, SE008 |
| CE016 | Public sources repeatedly describe lorecivivint as safe and well tolerated, but the chapter still relies mostly on trial summaries and publications rather than detailed safety datasets. | 高 | SE003, SE005, SE023 |
| CE017 | ClinicalTrials.gov records show randomized, blinded, placebo-controlled OA trial designs, which are trust-supporting process controls for evidence generation. | 高 | SE016, SE017, SE018, SE019 |
| CE018 | No reviewed public source provides detailed commercial-scale manufacturing, supply-chain, or CMC disclosure for lorecivivint. | 中 | SE001, SE002, SE008 |
| CE019 | No reviewed public source provides a public status page, uptime metric, or commercial support-operation disclosure analogous to software infrastructure companies. | 中 | SE001, SE002 |
| CE020 | The ACR and OARSI poster trail shows a sustained practitioner-facing publication cadence around lorecivivint and related programs from 2015 through 2025. | 中 | SE009, SE010, SE013, SE014, SE015 |
| CE021 | That practitioner-facing cadence is a reasonable developer-signal proxy for a biotech platform that does not expose a public code repository or API community. | 中 | SE002, SE009, SE010 |
| CE022 | Peer-reviewed publications carry more evidentiary weight than conference posters, but the poster sequence is still useful for roadmap freshness and scientific engagement. | 中 | SE023, SE025, SE010, SE013 |
| CE023 | External literature across Sage, Taylor & Francis, and OARSI sources shows independent scientific discussion around lorecivivint and OA disease-modification questions, broadening the technical context beyond company-authored materials. | 中 | SE026, SE027, SE029 |
| CE024 | CDC arthritis statistics reinforce that Biosplice is building for a large chronic disease context, but they do not solve the chapter's missing manufacturing and launch-readiness evidence. | 中 | SE028, SE029 |
| CE025 | The 2020 through 2021 publication set supports early technical maturity, while 2022 through 2026 materials show the program grappling with late-stage proof and label-shaping issues. | 中 | SE005, SE003, SE006, SE007, SE008 |
| CE026 | The product chapter can verify trial design, mechanism framing, and milestone sequence, but not validated commercial manufacturing readiness. | 中 | SE016, SE018, SE008 |
| CE027 | Biosplice's public product architecture for OA consists of a single injection asset, a trial/evidence system, regulatory review, and eventual specialist administration rather than a multi-module device stack. | 中 | SE001, SE018, SE008 |
| CE028 | The oncology side of the platform uses oral administration in some studies, which shows that the underlying splicing approach is not tied to one route of delivery. | 中 | SE020, SE021 |
| CE029 | The company's public mechanism narrative starts from Wnt pathway modulation and links it to alternative pre-mRNA splicing control. | 中 | SE009, SE004 |
| CE030 | The lorecivivint evidence package appears strongest when structure, pain, and function move together, and weakest when pain endpoints miss despite other signals. | 中 | SE005, SE006, SE007 |
| CE031 | Because the product is administered by clinicians in trials, deployment risk is more about approval, reimbursement, and site readiness than about patient self-onboarding. | 中 | SE018, SE019, SE008 |
| CE032 | The 2025 ACR program and the active AML study support the view that Biosplice continues to invest in platform breadth even while the OA asset approaches review. | 中 | SE014, SE022 |
| CE033 | Public sources do not show external manufacturing partners, cold-chain requirements, or finished-product release metrics, leaving a meaningful product-risk blind spot. | 中 | SE001, SE002, SE008 |
| CE034 | The existence of multiple phase 2 and phase 3 OA trials, plus an NDA filing, supports high maturity for clinical development but not yet for commercial operations. | 高 | SE016, SE017, SE018, SE019, SE008 |
| CE035 | The product roadmap from public evidence is clear on past clinical milestones and current regulatory review, but unclear on launch support infrastructure and manufacturing scale-up. | 中 | SE008, SE002, SE001 |
| CE036 | The most important public trust controls are blinded randomized study design and repeated external publication rather than public operational certifications. | 中 | SE016, SE018, SE023, SE025 |
| CE037 | The strongest public differentiation claim is not software-like product complexity but a first-in-class therapeutic mechanism pursued across multiple indications. | 中 | SE009, SE002, SE022 |
| CE038 | The weakest part of the public product record is post-approval operating detail: manufacturing, quality-system specifics, pharmacovigilance process detail, and commercial support readiness remain mostly private. | 中 | SE008, SE002 |
| CE039 | Overall, Biosplice's product story is technically distinctive and clinically mature, but still operationally opaque where commercialization quality systems should become visible. | 中 | SE008, SE023, SE018, SE002 |
| CU001 | Biosplice does not yet show a public commercial patient base for lorecivivint; the most visible current "customers" are regional commercialization partners and clinical stakeholders. | 高 | SU001, SU002, SU003, SU004 |
| CU002 | Haisco is the named China commercialization partner for lorecivivint. | 中 | SU003, SU005, SU006 |
| CU003 | Samil is the named Korea commercialization partner for lorecivivint. | 中 | SU004, SU007, SU008 |
| CU004 | Those partner relationships provide proof of external commercial interest, but not proof of current commercial sales or renewals. | 中 | SU003, SU004, SU005 |
| CU005 | The Haisco and Samil relationships also imply that Biosplice's earliest visible customer concentration is geographic and partner-driven. | 中 | SU003, SU004 |
| CU006 | ClinicalTrials.gov study records show large multicenter site networks for the OA studies, which is evidence of broad investigator participation even before commercialization. | 高 | SU020, SU019, SU018 |
| CU007 | The OA-02 study enrolled 455 participants, indicating meaningful early patient participation for a private biotech program. | 高 | SU020, SU016 |
| CU008 | STRIDES-1 enrolled 496 participants, showing continued willingness of investigators and patients to participate in late-stage lorecivivint development. | 高 | SU019, SU015 |
| CU009 | STRIDES-X-ray and related long-term studies support repeat follow-up engagement, but this is still a trial-retention proxy rather than a commercial renewal metric. | 中 | SU018, SU014, SU018 |
| CU010 | The PMC post-hoc analysis shows that more participants treated with 0.07 mg lorecivivint achieved clinically meaningful pain and function responses than placebo recipients. | 中 | SU010 |
| CU011 | The placebo-versus-sham paper demonstrates that substantial patient-reported improvement can also arise within control arms, which tempers simplistic customer-satisfaction readings from OA trials. | 中 | SU013 |
| CU012 | The 2026 meta-analysis reported modest pain improvement but no consistent benefit across all functional or structural outcomes, adding further caution to any broad adoption claim. | 中 | SU011 |
| CU013 | The 2020 review article still framed lorecivivint as potentially safe and well tolerated, but emphasized that phase 3 trials would determine real commercial relevance. | 中 | SU012 |
| CU014 | Biosplice's customer story is therefore still more clinical than commercial: patient response, investigator participation, and partner option value matter more than booked accounts. | 中 | SU010, SU019, SU003, SU004 |
| CU015 | NCI-sponsored cirtuvivint work creates a different kind of stakeholder proof: institutional adoption of a study rather than product purchase. | 高 | SU017, SU021, SU022, SU023 |
| CU016 | First-patient-dosed announcements in the NCI-sponsored AML/MDS study are proof of operational activation, but not revenue-generating customer adoption. | 中 | SU023, SU022 |
| CU017 | No retained source provides active treated commercial patient counts for lorecivivint. | 中 | SU002, SU001 |
| CU018 | No retained source provides NRR, GRR, churn, or contract-renewal metrics. | 中 | SU003, SU004 |
| CU019 | No retained source provides public customer-satisfaction surveys outside trial outcome instruments. | 中 | SU010, SU013 |
| CU020 | The named-partner proof quality is higher than logo-only proof because both Haisco and Samil are tied to specific rights, geographies, and stated economics. | 中 | SU003, SU004, SU005, SU007 |
| CU021 | The named-patient and investigator proof quality is also stronger than generic marketing because the retained sources tie responses to registered trials and published analyses. | 中 | SU010, SU015, SU014, SU011 |
| CU022 | Even so, the chapter should not overstate trial participation as customer adoption because trial subjects are not paying commercial users. | 中 | SU020, SU019, SU010 |
| CU023 | Public partner concentration risk is high because the ex-US commercialization story rests on a small number of named counterparties. | 中 | SU003, SU004, SU005 |
| CU024 | Asset concentration risk is also high because the visible customer story is dominated by one lead OA asset. | 中 | SU001, SU002 |
| CU025 | The public adoption trajectory is milestone-based rather than account-based: phase 2 participation, phase 3 participation, partner deals, and NDA filing. | 中 | SU020, SU019, SU003, SU004, SU002 |
| CU026 | There is no public evidence of repeat purchasing, reorder rates, or contract expansion for a commercial lorecivivint business. | 中 | SU003, SU004, SU002 |
| CU027 | Trial follow-up durations and crossover designs offer only weak proxies for durability because they test engagement under protocol rather than customer willingness to repurchase. | 中 | SU018, SU013 |
| CU028 | The PubMed search result set shows a real body of external literature around lorecivivint, which supports stakeholder awareness even though it does not prove market adoption. | 中 | SU024, SU012, SU011 |
| CU029 | The ACR on Air episode provides a practitioner-attention signal, suggesting that rheumatology audiences are at least aware of the program. | 中 | SU025 |
| CU030 | Public buyer and payer proof remains thin relative to partner and patient proof; the clearest payer references still come indirectly through future access discussions rather than executed contracts. | 中 | SU002, SU004 |
| CU031 | If approved, the likely customer chain would separate partner/licensee, prescribing clinician, payer, and patient rather than collapse them into one actor. | 中 | SU003, SU004, SU015 |
| CU032 | Biosplice's strongest named-customer-style evidence is therefore not current revenue accounts but counterparties willing to license rights and institutions willing to run studies. | 中 | SU003, SU004, SU022, SU015 |
| CU033 | Current visible customer segments are partner pharma companies, clinical investigators/sites, patients in registered studies, and future payers still lacking hard public proof. | 中 | SU003, SU004, SU015, SU010 |
| CU034 | China and Korea are the named ex-US partner geographies in the retained source set. | 中 | SU003, SU004 |
| CU035 | The NCI-sponsored AML study expands stakeholder proof beyond OA and shows that external institutions will operationalize the company's programs. | 中 | SU022, SU017, SU023 |
| CU036 | Commercial treated-patient count should be recorded as null rather than zero, because the product is not commercially launched and no public count is disclosed. | 中 | SU002, SU001 |
| CU037 | Reference quality is highest where a named partner or named study is corroborated by at least one independent domain. | 中 | SU003, SU005, SU004, SU007, SU015, SU010 |
| CU038 | Overall, the customer chapter supports real stakeholder pull but not yet a diversified, measurable commercial customer base. | 中 | SU003, SU004, SU010, SU002 |
| CR001 | The core regulatory risk is that NDA submission does not guarantee approval, label breadth, or timing. | 中 | SR001, SR003 |
| CR002 | Mixed OA-10 and OA-11 all-comer results materially weaken a simple efficacy narrative. | 高 | SR002, SR004, SR005 |
| CR003 | OA-21's 12-week primary pain miss shows late-stage endpoint sensitivity remains a live risk even after positive structural narratives. | 中 | SR003 |
| CR004 | The meta-analysis adds independent caution by reporting only modest pain improvement and no consistent benefit across all outcomes. | 中 | SR025 |
| CR005 | Placebo-versus-sham results show that control-arm improvement can be large in knee-OA injection trials, complicating signal interpretation and future commercialization claims. | 中 | SR026 |
| CR006 | If approval is delayed or the label is narrow, the commercialization timetable and financing posture could deteriorate quickly. | 中 | SR001, SR017 |
| CR007 | ClinicalTrials.gov and NCI sources confirm the company operates within a highly regulated environment across OA and oncology programs. | 中 | SR009, SR004, SR007, SR028 |
| CR008 | The patent record confirms Biosplice owns a non-trivial body of assigned patents, but public assignment lists do not prove enforceability or freedom to operate. | 中 | SR014, SR015 |
| CR009 | No retained source surfaced active litigation or enforcement against the company, but that absence is weaker than a targeted docket search. | 中 | SR014, SR015 |
| CR010 | The missing public terms-of-use and privacy-policy pages create a small but real governance/transparency concern for external diligence. | 高 | SR012, SR013 |
| CR011 | A missing company-hosted NDA news permalink on the public website is another minor but visible web-governance gap. | 中 | SR031 |
| CR012 | For a biotech this web-governance gap is not thesis-breaking on its own, but it weakens confidence in outward-facing compliance hygiene. | 中 | SR012, SR013 |
| CR013 | Manufacturing, CMC, and launch-support systems remain largely opaque in public materials, which is a meaningful operational risk near commercialization. | 中 | SR023, SR001 |
| CR014 | The missing CMS coverage page and lack of public payer contracts underline that access and reimbursement proof remain unresolved. | 中 | SR011, SR001 |
| CR015 | Biosplice is highly concentrated on a single lead OA asset for near-term value realization. | 中 | SR023, SR001 |
| CR016 | Partner concentration is also high because the named ex-US commercialization story depends on a small number of counterparties broadly. | 中 | SR021, SR022, SR020 |
| CR017 | The public financial-model risk is elevated because Form D filings and press releases do not reveal current cash, monthly burn, or runway months. | 高 | SR016, SR017, SR001 |
| CR018 | The reported 2026 retail raise remains weakly supported and should be treated as a risk-amplifying uncertainty rather than confirmed mitigation. | 中 | SR019, SR017, SR001 |
| CR019 | The terminated SM08502 combination study is an adverse portfolio signal because it shows business reasons can halt programs even when scientific questions remain open. | 中 | SR007 |
| CR020 | Partner deals partly mitigate funding and market-entry risk by creating external validation and regional execution channels. | 中 | SR021, SR022, SR020 |
| CR021 | Partner deals also amplify dependency risk because a few counterparties can shape ex-US execution quality and economics. | 中 | SR021, SR022 |
| CR022 | The strongest operational proof today is the company's ability to run large multicenter studies and sustain external investigator participation. | 高 | SR006, SR004, SR005 |
| CR023 | That proof does not automatically translate into launch excellence, payer access, or post-approval pharmacovigilance readiness. | 中 | SR004, SR001 |
| CR024 | The most direct thesis-break triggers are approval delay, weak label, poor reimbursement, failure to validate cash adequacy, and partner underperformance. | 中 | SR001, SR011, SR017, SR021 |
| CR025 | Competitive and clinical setbacks in the broader OA field, cited by Fierce, suggest that late-stage failure risk in this indication is not theoretical. | 中 | SR020 |
| CR026 | The company's own forward-looking statements explicitly warn that regulatory review and commercialization outcomes remain uncertain. | 中 | SR001 |
| CR027 | A weak payer-access outcome could compress pricing, slow adoption, and reduce the value of both U.S. and ex-US partnerships. | 中 | SR011, SR021, SR022 |
| CR028 | If approval slips, the company may need more capital before meaningful product revenue arrives, increasing dilution risk. | 中 | SR001, SR017, SR018 |
| CR029 | If partner execution underperforms, geographic optionality shrinks and concentration risk becomes more punitive. | 中 | SR021, SR022 |
| CR030 | The public patent record is a supporting moat signal, but not a substitute for asset-specific legal diligence on scope, expiry, and enforceability. | 中 | SR014, SR015 |
| CR031 | The risk stack that transmits most directly into valuation is regulatory risk first, followed by financing opacity, payer access, and partner concentration. | 中 | SR001, SR017, SR011, SR021 |
| CR032 | Missing public web policies are small relative to drug-approval risk, but they are unusual enough to preserve as a diligence item. | 中 | SR012, SR013 |
| CR033 | No retained source provides a definitive public launch-readiness checklist covering manufacturing, supply, medical affairs, and pharmacovigilance. | 中 | SR001, SR023 |
| CR034 | No retained source proves active payer coverage, CMS coding, or formulary wins for lorecivivint. | 中 | SR011, SR001 |
| CR035 | The combination of a single lead OA asset and opaque cash position makes financing risk harder to separate from regulatory risk. | 中 | SR023, SR017, SR001 |
| CR036 | Because the customer story is still pre-commercial, customer concentration and reimbursement risks will not be fully observable until after approval. | 中 | SR021, SR022, SR001 |
| CR037 | The NCI-sponsored oncology collaboration is a positive institutional signal, but it does little to reduce the OA launch-risk stack. | 中 | SR028, SR029, SR001 |
| CR038 | Operational diligence should focus on CMC, supply chain, safety operations, and launch staffing rather than additional generic market-size work. | 中 | SR001, SR023 |
| CR039 | Public-data precision is lowest on cash adequacy, legal exposure beyond patent assignments, and exact payer readiness. | 中 | SR017, SR014, SR011 |
| CR040 | On balance, Biosplice faces a credible but concentrated risk stack typical of late-stage biotech, with approval and commercialization execution as the two decisive variables. | 中 | SR001, SR003, SR017, SR021 |
| CR041 | The absence of active-litigation proof should be treated as an open diligence path, not an all-clear signal. | 中 | SR014, SR015 |
| CR042 | The public risk record already justifies a high residual-severity score for approval, financing, and access risks even before full internal diligence. | 中 | SR001, SR017, SR011 |
| CV001 | Lorecivivint had an NDA on file by January 2026, but public sources reviewed for this run do not show final approval or commercial launch metrics. | 高 | SV001, SV002, SV003, SV027, SV018, SV021 |
| CV002 | The most widely corroborated historic equity mark is Samumed's August 2018 $438M round at a reported $12B pre-money valuation. | 中 | SV032, SV025, SV034 |
| CV003 | Biosplice publicly announced a $120M equity financing in April 2021. | 高 | SV004, SV025, SV034 |
| CV004 | SEC Form D filings in 2021 and 2022 corroborate that financing activity continued after the rebrand, but they do not disclose a current enterprise value. | 高 | SV006, SV007 |
| CV005 | Tracxn's funding page reports $778M total funding across three rounds, with the latest $120M round on April 15, 2021. | 中 | SV025 |
| CV006 | Dealroom still labels Biosplice a decacorn and reports roughly ten investors on the cap table, but explicitly describes the ownership data as estimated. | 中 | SV011 |
| CV007 | UpMarket presents a $12.44B latest price reference and an $11B platform estimate, both framed as model- or reference-based rather than a freshly priced round. | 中 | SV009 |
| CV008 | Notice provides a $4.87 per-share style private-market headline, but the retained page does not turn that into audited intrinsic value. | 中 | SV008 |
| CV009 | The public tracker stack appears to lean on stale private references and model outputs rather than a newly disclosed priced financing. | 中 | SV009, SV008, SV011, SV025 |
| CV010 | Seedtable's Biosplice and Samumed pages show that tracker summaries disagree on the number of rounds and investors, reinforcing that these pages are context, not a cap table. | 中 | SV012, SV035 |
| CV011 | Tracxn's company profile lists Biosplice at Series B stage and shows multiple active legal entities with dated employee counts, which is useful context but not a live underwriting model. | 中 | SV034 |
| CV012 | VentureRadar frames Biosplice as a privately held Wnt/RNA platform and surfaces similarity peers such as Surrozen, Skyhawk, Frequency Therapeutics, and Arrakis. | 中 | SV033 |
| CV013 | Caplight surfaces OrthoTrophix, Kolon TissueGene, and Eupraxia as similarity-based comparables rather than direct priced substitutes. | 中 | SV010 |
| CV014 | The Haisco licensing transaction was publicly described as worth up to $140M, including $20M in upfront and early development milestones. | 高 | SV014, SV015 |
| CV015 | The Samil transaction was publicly described as worth up to $70M in aggregate value. | 高 | SV016, SV017 |
| CV016 | Those regional licensing economics are meaningful validation, but on their own they do not justify an $11B-$12B equity value for the whole company. | 中 | SV014, SV015, SV016, SV017 |
| CV017 | Synapse lists lorecivivint as an NDA/BLA-stage program in the United States as of January 2026, which supports late-stage value but not approval certainty. | 中 | SV027, SV001 |
| CV018 | Synapse's organization profile indicates Biosplice still has multiple non-OA programs, so there is platform optionality beyond lorecivivint. | 中 | SV026 |
| CV019 | Synapse also shows cirtuvivint still in phase 2 and related oncology settings, which makes that program more like option value than near-term cash-flow support. | 中 | SV028 |
| CV020 | Three retained alopecia studies show Biosplice advanced SM04554 through multiple phase 2 and phase 2/3 studies, illustrating breadth but also the age and non-core nature of some legacy pipeline work. | 中 | SV029, SV030, SV031 |
| CV021 | The retained clinical evidence does not support a clean premium multiple because the public record still includes mixed late-stage OA outcomes and an adverse meta-analysis. | 中 | SV018, SV019, SV020 |
| CV022 | Public sources reviewed for this report do not disclose product revenue, realized launch pricing, gross margin, or commercial uptake for lorecivivint. | 高 | SV001, SV002, SV021 |
| CV023 | Public sources also do not disclose current cash on hand, monthly burn, or runway months. | 高 | SV006, SV007, SV025, SV011 |
| CV024 | No retained source provides a live preference stack, option-pool terms, or liquidation waterfall for Biosplice. | 中 | SV011, SV012, SV035 |
| CV025 | The July 2026 retail-raise narrative remains weakly supported and should not be used as a primary valuation anchor until primary transaction evidence appears. | 中 | SV013, SV007, SV025 |
| CV026 | Across 2018, 2021, and 2022 evidence, Biosplice clearly had repeated access to private capital. | 高 | SV005, SV004, SV006, SV007 |
| CV027 | That historical access to capital does not itself prove what price a new investor should pay today. | 中 | SV005, SV004, SV025, SV009 |
| CV028 | UpMarket explicitly warns that private-share transactions are illiquid, speculative, and can result in total loss of capital. | 中 | SV009 |
| CV029 | Dealroom's estimated $170M patent-portfolio figure and 70 active patent families indicate asset depth, but not directly monetizable equity value. | 中 | SV011, SV022 |
| CV030 | Patent and platform breadth help explain why Biosplice attracted large historical funding, but they do not bridge approval, access, or financing-opacity risks. | 中 | SV011, SV022, SV026 |
| CV031 | The positive thesis is that Biosplice combines a late-stage OA asset, real regional partner economics, and a historically exceptional funding record. | 中 | SV001, SV014, SV016, SV032, SV004 |
| CV032 | The anti-thesis is that the visible valuation stack is stale, tracker-driven, and unsupported by current cash-flow, cap-table, or launch-disclosure evidence. | 中 | SV009, SV008, SV011, SV007, SV020 |
| CV033 | A supportable bull case requires approval, a workable label, reimbursement traction, validated launch readiness, and investor-friendly terms. | 中 | SV001, SV002, SV009 |
| CV034 | A supportable base case is to maintain access and diligence rights while withholding a buy judgment until private metrics convert tracker context into real underwriting. | 中 | SV009, SV011, SV025 |
| CV035 | A supportable bear case is that approval slips or access disappoints, forcing additional financing against a stale private mark. | 中 | SV020, SV007, SV009, SV013 |
| CV036 | The comp evidence is too heterogeneous for a clean revenue or asset multiple because the surfaced peers span Wnt regenerative biotechs, RNA companies, and secondary-market private profiles. | 中 | SV010, SV033, SV034 |
| CV037 | Non-OA pipeline programs should be treated as upside optionality or free call options rather than core justification for today's entry price. | 中 | SV026, SV028, SV023, SV024 |
| CV038 | The 2018 $12B mark is best treated as historical ceiling context rather than current fair value. | 中 | SV032, SV025, SV009 |
| CV039 | Current public evidence does not support underwriting an $11B-$12B entry with high confidence. | 中 | SV009, SV008, SV011, SV020, SV007 |
| CV040 | The highest-value diligence asks now are a signed term sheet, current cap table, cash bridge, label scenarios, pricing and reimbursement plan, and launch-readiness package. | 中 | SV007, SV009, SV002, SV011 |
| CV041 | The recommendation that follows from the public record is research-more / track rather than buy. | 中 | SV009, SV011, SV007, SV020 |
| CV042 | Confidence should be medium-low: the financing history and stage are well evidenced, but current valuation evidence is indirect and incomplete. | 中 | SV032, SV004, SV007, SV009, SV011 |
| CV043 | If private diligence shows weak cap-table cleanliness or inadequate runway, the investment thesis should break quickly. | 中 | SV007, SV011, SV009 |
| CV044 | If private diligence shows ordinary terms, adequate runway, and launch readiness at a materially lower entry, the recommendation could improve. | 中 | SV009, SV002, SV011 |